FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Hagop Kantarjian

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Anatomy

Philadelphia Chromosome

Physiology

Drug Resistance, Neoplasm

Co-author Network

Publications

TOP 3
Andreas Hochhaus; Albert Hoenekopp; Carmino De Souza; Gabriel Etienne; Xiaolin Fan; Matt E Kalaycio; Hagop M Kantarjian; Dong-Wook Kim; Mineo Kurokawa; Richard A Larson; Gianantonio Rosti; Giuseppe Saglio; Yaping Shou; Timothy P Hughes
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Srdan Verstovsek; Elliott F Winton; Murat O Arcasoy; John V Catalano; Michael Deininger; John F Dipersio; Susan Erickson-Viitanen; Jason Gotlib; Vikas Gupta; Jimmie H Harvey; Elizabeth Hexner; Richard S Levy; Roger M Lyons; Ruben A Mesa; Carole Miller; Ronald Paquette; Azra Raza; Victor Sandor; Richard T Silver; William Sun; Moshe Talpaz; Kris Vaddi; Hagop M Kantarjian
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
Jorge Cortes; A R Craig; Raghunadharao Digumarti; Andreas Hochhaus; Hagop M Kantarjian; J H Lipton; F E Nicolini; P M Parikh; Meir Wetzler; A-C Benichou
Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Hagop Kantarjian (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Andreas Hochhaus; Albert Hoenekopp; Carmino De Souza; Gabriel Etienne; Xiaolin Fan; Matt E Kalaycio; Hagop M Kantarjian; Dong-Wook Kim; Mineo Kurokawa; Richard A Larson; Gianantonio Rosti; Giuseppe Saglio; Yaping Shou; Timothy P Hughes
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Blood 2013;121(18):3703-8.
2013: Srdan Verstovsek; Elliott F Winton; Murat O Arcasoy; John V Catalano; Michael Deininger; John F Dipersio; Susan Erickson-Viitanen; Jason Gotlib; Vikas Gupta; Jimmie H Harvey; Elizabeth Hexner; Richard S Levy; Roger M Lyons; Ruben A Mesa; Carole Miller; Ronald Paquette; Azra Raza; Victor Sandor; Richard T Silver; William Sun; Moshe Talpaz; Kris Vaddi; Hagop M Kantarjian
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
British journal of haematology 2013;161(4):508-16.
2013: Jorge Cortes; A R Craig; Raghunadharao Digumarti; Andreas Hochhaus; Hagop M Kantarjian; J H Lipton; F E Nicolini; P M Parikh; Meir Wetzler; A-C Benichou
Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors.
American journal of hematology 2013;88(5):350-4.
2013: Ruben A Mesa; Carole B Miller; Victor Sandor; Alan L Shields; Richard T Silver; William Sun; Moshe Talpaz; John V Catalano; Michael W Deininger; Susan Erickson-Viitanen; Jason Gotlib; Vikas Gupta; Thomas Hare; Jimmie H Harvey; Hagop M Kantarjian; Richard S Levy; Elliott F Winton; Srdan Verstovsek
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(10):1285-92.
2013: Elias Jabbour; M Baccarani; Kapil N Bhalla; Jorge Cortes; N Gattermann; Francis Giles; A Hochhaus; T P Hughes; D-W Kim; R A Larson; P D le Coutre; giovanni martinelli; O G Ottmann; Javier Pinilla-Ibarz; J P Radich; John Reynolds; G Saglio; R C Woodman; Hagop M Kantarjian
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance.
Leukemia 2013;27(4):907-13.
2013: Francis J Giles; Michele Baccarani; Philipp D le Coutre; Oliver G Ottmann; William M Sallas; Richard C Woodman; Ophelia Q P Yin; Hagop M Kantarjian
Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia.
European journal of clinical pharmacology 2013;69(4):813-23.
2013: Roland B Walter; Frederick R Appelbaum; Alan K Burnett; Anna Evans; Robert K Hills; Hagop M Kantarjian; Bob Löwenberg; Gert J Ossenkoppele; Megan Othus; Sherry R Pierce; Farhad Ravandi; Kees G M van Montfort; Elihu H Estey
Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients.
Blood 2013;121(13):2424-31.
2013: Hagop M Kantarjian; Richard A Larson; Jorge E Cortés; Kathleen L Deering; Michael J Mauro
Current practices in the management of chronic myeloid leukemia.
Clinical lymphoma, myeloma & leukemia 2013;13(1):48-54.
2013: Naval Daver; Rodney Haltom; Hagop M Kantarjian; Aziz Nazha; Farhad Ravandi
Treatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options.
Clinical lymphoma, myeloma & leukemia 2013;13(1):86-9.
2013: Hun Ju Lee; Naval Daver; Hagop M Kantarjian; Srdan Verstovsek; Farhad Ravandi
The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(2):327-35.
2013: Pamela S Becker; Frederick R Appelbaum; Stephan Faderl; Hagop M Kantarjian; Sherry Pierce; Jianqin Shan; Barry Storer; Elihu H Estey
Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia.
Haematologica 2013;98(1):114-8.
2013: Sergej Konoplev; Marina Konopleva; Steven M Kornblau; Gary Lu; Rajyalakshmi Luthra; L Jeffrey Medeiros; C Cameron Yin; Zhuang Zuo; Michael Andreeff; Hagop M Kantarjian; Carlos E Bueso-Ramos
Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia.
Leukemia & lymphoma 2013;54(1):138-44.
2012: Susan Branford; Ariful Haque; Andreas Hochhaus; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Giovanni Martinelli; Jerald P Radich; Giuseppe Saglio; Yaping Shou; Simona Soverini; Richard C Woodman; Martin C Müller
Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(35):4323-9.
2012: Daniela Hoehn; Hagop M Kantarjian; L Jeffrey Medeiros; Xuemei Wang; Jorge E Cortes; Carlos E Bueso-Ramos
Digital image analysis as a tool to assess the effects of imatinib on trabecular bone in patients with chronic myelogenous leukemia.
Human pathology 2012;43(12):2354-9.
2012: Farhad Ravandi; Charles Alan Schiffer; Richard A Larson; Francesco Lo Coco; Frederick R Appelbaum; Alan K Burnett; Elihu H Estey; Hagop M Kantarjian
Gemtuzumab ozogamicin: time to resurrect?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(32):3921-3.
2012: Yi Zhou; L Jeffrey Medeiros; Farhad Ravandi; Sa A Wang; Jorge Cortes; Jeffrey L Jorgensen; Hagop M Kantarjian; Sergej Konoplev
Usefulness of CD11a and CD18 in flow cytometric immunophenotypic analysis for diagnosis of acute promyelocytic leukemia.
American journal of clinical pathology 2012;138(5):744-50.
2012: Jorge E Cortes; Athena Countouriotis; Irina Dyagil; Karïn Gogat; Laimonas Griskevicius; Hagop M Kantarjian; Dong-Wook Kim; Hemant Malhotra; Christine Powell; Tim H Brümmendorf; Carlo Gambacorti-Passerini
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(28):3486-92.
2012: Richard A Larson; B Moiraghi; Giuseppe Saglio; R Yu; D-W Kim; M Kurokawa; R E Blakesley; R E Clark; G Etienne; Ian W Flinn; N J Gallagher; A Hochhaus; T P Hughes; Hagop M Kantarjian
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.
Leukemia 2012;26(10):2197-203.
2012: Mikako Warren; C Cameron Yin; Jorge E Cortes; Hagop M Kantarjian; Rajyalakshmi Luthra; L Jeffrey Medeiros; Farhad Ravandi; Zhuang Zuo
Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2012;25(10):1405-12.
2012: Ohad Benjamini; Zeev Estrov; Preetesh Jain; Hagop M Kantarjian; Srdan Verstovsek
Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly.
Blood 2012;120(13):2768-9.
2012: Stefan Faderl; Jennie Feliu; Alessandra Ferrajoli; Guillermo Garcia-Manero; Xuelin Huang; Elias Jabbour; Tapan Kadia; Gautam Borthakur; Jan Burger; Marina Konopleva; Farhad Ravandi; Xuemei Wang; Hagop M Kantarjian
Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
Cancer 2012;118(18):4471-7.
2012: Michael S Mathisen; Elias Jabbour; Hagop M Kantarjian
Treatment of adult acute lymphoblastic leukemia (ALL) with a focus on emerging investigational and targeted therapies.
Oncology (Williston Park, N.Y.) 2012;26(9):851-9.
2012: Srdan Verstovsek; Sherry Pierce; Ester Pungolino; Elisa Rumi; Deborah A Thomas; Gautam Borthakur; Domenica Caramazza; Mario Cazzola; Jorge E Cortes; Zeev Estrov; Elias Jabbour; Tapan Kadia; Hagop M Kantarjian; Enrica Morra; Francesco Passamonti
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
Blood 2012;120(6):1202-9.
2012: Ophelia Q P Yin; Philipp le Coutre; Giuseppe Saglio; Michele Baccarani; Ovidiu Chiparus; Neil Gallagher; Frank J Giles; Andreas Hochhaus; Timothy P Hughes; Hagop M Kantarjian; Richard A Larson
Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia.
Cancer chemotherapy and pharmacology 2012;70(2):345-50.
2012: Hagop M Kantarjian; Ching-Yuan Kuo; Daniel Lysák; Jiri Mayer; Grzegorz Mazur; Mark Minden; Albert Oriol; Farhad Ravandi; Xavier G Thomas; Agnieszka Wierzbowska; Rena Buckstein; Jaroslav Cermak; Wen-Chien Chou; Jacques Delaunay; Anna Dmoszynska; Stefan Faderl; Jyh-Pyng Gau; Christopher Arthur
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(21):2670-7.
2012: Stefan Faderl; Siddhartha Ganguly; Stuart Goldberg; Jochen Greiner; Parameswaran Hari; Dirk Huebner; Madan Jagasia; Tibor Kovacsovics; Michael Maris; Farhad Ravandi; Christian Recher; David A Rizzieri; Gary Schiller; Karen Seiter; Robert Stuart; Michael Vasconcelles; Norbert Vey; Eunice S Wang; Meir Wetzler; David Avigan; Robert Collins; Michael Craig; Hagop M Kantarjian
Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(20):2492-9.
2012: Bing Z Carter; Kevin R Coombes; Jorge Cortes; Lixia Diao; Xuelin Huang; Hagop M Kantarjian; Marina Konopleva; Duncan H Mak; Gordon B Mills; Yihua Qiu; Nianxiang Zhang; Michael Andreeff; Steven M Kornblau
Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML.
Blood 2012;120(1):173-80.
2012: Xiaodong Cheng; Emil J Freireich; Ming-Zhang Gao; Mirna Golemovic; Hagop M Kantarjian; Alfonso Quintás-Cardama; Michael Andreeff; Ralph Zingaro; Srdan Verstovsek
The organic arsenic derivative GMZ27 induces PML-RARα-independent apoptosis in myeloid leukemia cells.
Anticancer research 2012;32(7):2871-80.
2012: Rajesh R Singh; Ashish Bains; Bedia A Barkoh; Tigist Bisrat; Jorge E Cortes; Hagop M Kantarjian; L Jeffrey Medeiros; Abhaya Paladugu; Keyur P Patel; Hamed Rahimi; Farhad Ravandi-Kashani; Rajyalakshmi Luthra
Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis.
The Journal of molecular diagnostics : JMD 2012;14(4):336-45.
2012: Guillermo Garcia-Manero; Yumin Hu; Elias Jabbour; Tapan M Kadia; Nebiyou B Bekele; Gautam Borthakur; Mark Brandt; Jorge E Cortes; Marcos de Lima; Stefan Faderl; Marina Y Konopleva; Deborah McCue; Willie Mae Newsome; Sherry R Pierce; Farhad Ravandi; Francesco Paolo Tambaro; Hui Yang; Hagop M Kantarjian
Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(18):2204-10.
2012: Guilin Tang; Deborah A Thomas; Zhuang Zuo; Carlos Bueso-Ramos; Ying Hu; Hagop M Kantarjian; Pei Lin; Dingsheng Liu; L Jeffrey Medeiros; Sa A Wang
Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related?
Haematologica 2012;97(6):919-25.
2012: Hagop M Kantarjian; J Li; J K Altman; G Borthukar; G A Curt; Stefan Faderl; G Garcia-Manero; D Huszar; T Kadia; O Odenike; A Osmukhina; S Padmanabhan; K Sankhala; W Stock; M S Tallman; K Wu; M Minden
Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia.
Investigational new drugs 2012;30(3):1107-15.
2012: Alireza Eghtedar; Zeev Estrov; Stefan Faderl; Alessandra Ferrajoli; Solly George; Hagop M Kantarjian; Robert C Newton; Carol Bivins; Gautam Borthakur; Jan Burger; Jorge Cortes; Peggy A Scherle; Srdan Verstovsek; Farhad Ravandi
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.
Blood 2012;119(20):4614-8.
2012: Tapan M Kadia; Hagop M Kantarjian; Charles Koller; Sherry Pierce; Gautam Borthakur; Mark Brandt; Zeev Estrov; Stefan Faderl; Guillermo Garcia-Manero; Xuelin Huang; Elias Jabbour; Sergerrne York; Farhad Ravandi
Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome.
British journal of haematology 2012;157(3):312-20.
2012: Richard A Larson; Hirohisa Nakamae; Giuseppe Saglio; Ophelia Q P Yin; Richard E Clark; Eren Demirhan; Neil J Gallagher; Andreas Hochhaus; Timothy P Hughes; Hagop M Kantarjian; Philipp D le Coutre
Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase.
European journal of clinical pharmacology 2012;68(5):723-33.
2012: H Jean Khoury; Dong-Wook Kim; Eric Leip; Andrey Zaritskey; Jorge E Cortes; Athena Countouriotis; Carlo Gambacorti-Passerini; Hagop M Kantarjian; Virginia Kelly; Michele Baccarani; Nadine Besson; Tim H Brümmendorf
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
Blood 2012;119(15):3403-12.
2012: Srdan Verstovsek; Elliott F Winton; Murat O Arcasoy; John V Catalano; Michael Deininger; John F DiPersio; Susan Erickson-Viitanen; Jason Gotlib; Vikas Gupta; Jimmie H Harvey; Elizabeth Hexner; Iphigenia L Koumenis; Richard S Levy; Roger M Lyons; Ruben A Mesa; Carole B Miller; Ronald Paquette; Azra Raza; Victor Sandor; Richard T Silver; William Sun; Moshe Talpaz; Kris Vaddi; Hagop M Kantarjian
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
The New England journal of medicine 2012;366(9):799-807.
2012: Michael P Link; Karen Hagerty; Hagop M Kantarjian
Chemotherapy drug shortages in the United States: genesis and potential solutions.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(7):692-4.
2012: Hagop M Kantarjian; Dong-Wook Kim; Jorge H Milone; Franck E Nicolini; Michinori Ogura; Carolina Pavlovsky; Tadeusz Robak; Neil P Shah; María Soledad Undurraga; Jan Van Droogenbroeck; Edo Vellenga; Jianxiang Wang; Chao Zhu; Juan Julio Kassack Ipiña; Mohan B Agarwal; Michele Baccarani; M Brigid Bradley-Garelik; Jorge E Cortes; Christian Junghanss; Andreas Hochhaus
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
Blood 2012;119(5):1123-9.
2012: Jumpei Yamazaki; Marcos R Estecio; Lucy A Godley; Jaroslav Jelinek; Hagop M Kantarjian; Trisha Macrae; Kelly R Ostler; Lanlan Shen; Rodolphe Taby; Aparna Vasanthakumar; Jean-Pierre J Issa
Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia.
Epigenetics : official journal of the DNA Methylation Society 2012;7(2):201-7.
2012: Stefan Faderl; Varsha Gandhi; Guillermo Garcia-Manero; Elias Jabbour; Gautam Borthakur; Anna L Byrd; Jorge Cortes; Zeev Estrov; Monica Kwari; Farhad Ravandi; Hagop M Kantarjian
A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
Cancer 2012;118(3):722-8.
2011: Alfonso Quintás-Cardama; Jorgé E Cortes; Hagop M Kantarjian
Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase: long-term implications.
Cancer 2011;117(23):5261-70.
2011: Elias Jabbour; Hagop M Kantarjian; Susan O'Brien; Alfonso Quintás-Cardama; Mary Beth Rios; Jianqin Shan; Guillermo Garcia-Manero; Jorge E Cortes
Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(32):4260-5.
2011: William G Wierda; Charles A Koller; Susan Lerner; Susan O'Brien; Ellen Schlette; Deborah Thomas; Xuemei Wang; Lynne Abruzzo; Jan A Burger; Jorge Cortes; Kim-Anh Do; Stefan Faderl; Alessandra Ferrajoli; Guillermo Garcia-Manero; Hagop M Kantarjian; Michael J Keating
Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(31):4088-95.
2011: Susan M Wood; Stefan Faderl; Hagop M Kantarjian; Christina A Meyers; Sherry A Pierce; Guillermo Garcia-Manero
Association of anemia and cognitive dysfunction in patients with acute myelogenous leukemia and myelodysplastic syndrome.
American journal of hematology 2011;86(11):950-2.
2011: Jorge E Cortes; Richat Abbas; Steven Arkin; Nadine Besson; Tim H Brümmendorf; Hagop M Kantarjian; H Jean Khoury; Dong-Wook Kim; Eric Leip; Ricardo Pasquini; Zhi-Xiang Shen; Anna G Turkina; Angela Volkert; Junyuan Wang; Carlo Gambacorti-Passerini
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.
Blood 2011;118(17):4567-76.
2011: Sergej Konoplev; E Lin; L Jeffrey Medeiros; Deborah A Thomas; Michael Andreeff; Jan Burger; Jeffrey L Jorgensen; Hagop M Kantarjian; Marina Konopleva
Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia.
Cancer 2011;117(20):4689-95.
2011: Pamela S Becker; Frederick R Appelbaum; Stephan Faderl; Elizabeth Harrington; Paul C Hendrie; Hagop M Kantarjian; John M Pagel; Stephen H Petersdorf; Sherry Pierce; Jianqin Shan; Andrei R Shustov; Derek L Stirewalt; Barry Storer; Elihu H Estey
Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia.
British journal of haematology 2011;155(2):182-9.
2011: Stefan Faderl; David Harris; Inbal Hazan-Halevy; Hagop M Kantarjian; Zhiming Liu; Ashutosh Pal; William Bornmann; Carlos Bueso-Ramos; Diana V Ciurea; Zeev Estrov
Kit inhibitor APcK110 extends survival in an AML xenograft mouse model.
Investigational new drugs 2011;29(5):1094-7.
2011: Alfonso Quintás-Cardama; Ying Zhang; Zeev Estrov; Amos Gaikwad; David Harris; Hagop M Kantarjian; Taghi Manshouri; Srdan Verstovsek
Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.
Investigational new drugs 2011;29(5):818-26.
2011: Hagop M Kantarjian; Richard A Larson; Hirohisa Nakamae; Gianantonio Rosti; Giuseppe Saglio; Leif Stenke; Carmino De Souza; Rick E Blakesley; Ian W Flinn; Neil J Gallagher; Yeow Tee Goh; Andreas Hochhaus; Albert Hoenekopp; Timothy P Hughes
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
The lancet oncology 2011;12(9):841-51.
2011: Jesse Jaso; Jeffrey L Jorgensen; Hagop M Kantarjian; L Jeffrey Medeiros; Deborah A Thomas; Krista Cunningham; Sa A Wang
Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors.
Cancer 2011;117(17):4009-17.
2011: Kiran Naqvi; Guillermo Garcia-Manero; Sagar Sardesai; Jeong Oh; Carlos E Vigil; Sherry Pierce; Xiudong Lei; Jianqin Shan; Hagop M Kantarjian; Maria E Suarez-Almazor
Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(16):2240-6.
2011: Taghi Manshouri; Zeev Estrov; Alfonso Quintás-Cardama; Jan Burger; Ying Zhang; Ana Livun; Liza Knez; David Harris; Chad J Creighton; Hagop M Kantarjian; Srdan Verstovsek
Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor.
Cancer research 2011;71(11):3831-40.
2011: Jorge E Cortes; Andreas Hochhaus; Philipp D le Coutre; Gianantonio Rosti; Javier Pinilla-Ibarz; Elias Jabbour; Kathryn Gillis; Richard C Woodman; Rick E Blakesley; Francis J Giles; Hagop M Kantarjian; Michele Baccarani
Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib.
Blood 2011;117(21):5600-6.
2011: Elias Jabbour; Susan Branford; Giuseppe Saglio; Dan Jones; Jorge E Cortes; Hagop M Kantarjian
Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Cancer 2011;117(9):1800-11.
2011: Hagop M Kantarjian; Michele Baccarani; Elias Jabbour; Giuseppe Saglio; Jorge E Cortes
Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(7):1674-83.
2011: Isam Abdel-Karim; William K Plunkett; Susan O'Brien; Francis Giles; Deborah Thomas; Stefan Faderl; Farhad Ravandi; Mary Beth Rios; Min Du; Karen B Schneck; Victor J Chen; Boris K Lin; Steven J Nicol; Hagop M Kantarjian
A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia.
Investigational new drugs 2011;29(2):323-31.
2011: Jorge Cortes; Alfonso Quintás-Cardama; Hagop M Kantarjian
Monitoring molecular response in chronic myeloid leukemia.
Cancer 2011;117(6):1113-22.
2011: Michael S Mathisen; Hagop M Kantarjian; Jorge Cortes; Elias Jabbour
Mutant BCR-ABL clones in chronic myeloid leukemia.
Haematologica 2011;96(3):347-9.
2011: Stefan Faderl; Deborah Ann Thomas; Susan O'Brien; Farhad Ravandi; Guillermo Garcia-Manero; Gautam Borthakur; Alessandra Ferrajoli; Srdan Verstovsek; Mohamed Ayoubi; Michael Rytting; Jennie Feliu; Hagop M Kantarjian
Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy.
Clinical lymphoma, myeloma & leukemia 2011;11(1):54-9.
2011: Hui Yang; Zhihong Fang; Yue Wei; Yumin Hu; George A Calin; Hagop M Kantarjian; Guillermo Garcia-Manero
Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA.
American journal of hematology 2011;86(2):237-8.
2011: Hagop M Kantarjian; Francis J Giles; Kapil N Bhalla; Javier Pinilla-Ibarz; Richard A Larson; Norbert Gattermann; Oliver G Ottmann; Andreas Hochhaus; Jerald P Radich; Giuseppe Saglio; Timothy P Hughes; Giovanni Martinelli; Dong-Wook Kim; Yaping Shou; Neil J Gallagher; Rick Blakesley; Michele Baccarani; Jorge Cortes; Philipp D le Coutre
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.
Blood 2011;117(4):1141-5.
2011: Katja Karjalainen; Diana E Jaalouk; Carlos E Bueso-Ramos; Amado J Zurita; Akihiko Kuniyasu; Bedrich Eckhardt; Frank C Marini; Benjamin Lichtiger; Susan O'Brien; Hagop M Kantarjian; Jorge E Cortes; Erkki Koivunen; Wadih Arap; Renata Pasqualini
Targeting neuropilin-1 in human leukemia and lymphoma.
Blood 2011;117(3):920-7.
2011: Bing Z Carter; Yi Hua Qiu; Nianxiang Zhang; Kevin R Coombes; Duncan H Mak; Deborah A Thomas; Farhad Ravandi; Hagop M Kantarjian; Erich Koller; Michael Andreeff; Steven M Kornblau
Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML.
Blood 2011;117(3):780-7.
2011: Taichun Qin; Jingmin Shu; Jiali Si; Xiaodan Wang; Nianxiang Zhang; Ryan Castoro; Woonbok Chung; Samih El Ahdab; Rong He; Jaroslav Jelinek; Hagop M Kantarjian; Jean-Pierre J Issa
Mechanisms of resistance to decitabine in the myelodysplastic syndrome.
PloS one 2011;6(8):e23372.
2010: Hagop M Kantarjian; Deborah Thomas; Farhad Ravandi; Stefan Faderl; Elias Jabbour; Guillermo Garcia-Manero; Sherry Pierce; Jianquin Shan; Jorge Cortes; Susan O'Brien
Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration.
Cancer 2010;116(24):5568-74.
2010: Zhuang Zuo; Dan Jones; Hui Yao; Deborah A Thomas; Susan O'Brien; Farhad Ravandi; Hagop M Kantarjian; Lynne V Abruzzo; L Jeffrey Medeiros; Su S Chen; Rajyalakshmi Luthra
A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2010;23(11):1524-34.
2010: Hagop M Kantarjian; Francis J Giles; Peter L Greenberg; Ron L Paquette; Eunice S Wang; Janice L Gabrilove; Guillermo Garcia-Manero; Kuolung Hu; Janet L Franklin; Dietmar P Berger
Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy.
Blood 2010;116(17):3163-70.
2010: Deborah A Thomas; Susan O'Brien; Stefan Faderl; Guillermo Garcia-Manero; Alessandra Ferrajoli; William G Wierda; Farhad Ravandi; Srdan Verstovsek; Jeffrey L Jorgensen; Carlos E Bueso-Ramos; Michael Andreeff; Sherry Pierce; Rebecca Garris; Michael J Keating; Jorge Cortes; Hagop M Kantarjian
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3880-9.
2010: Nikolai Velev; Jorge Cortes; Richard Champlin; Dan Jones; Gabriela Rondon; Sergio Giralt; Gautam Borthakur; Hagop M Kantarjian; Marcos De Lima
Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.
Cancer 2010;116(15):3631-7.
2010: Tapan M Kadia; Hui Yang; Alessandra Ferrajoli; Sirisha Maddipotti; Claudia Schroeder; Timothy L Madden; Julianne L Holleran; Merrill J Egorin; Farhad Ravandi; Deborah A Thomas; Willie Newsome; Blanca Sanchez-Gonzalez; James Zwiebel; Igor Espinoza-Delgado; Hagop M Kantarjian; Guillermo Garcia-Manero
A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia.
British journal of haematology 2010;150(1):72-82.
2010: Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
The New England journal of medicine 2010;362(24):2251-9.
2010: Stefan Faderl; Guillermo Garcia-Manero; Zeev Estrov; Farhad Ravandi; Gautam Borthakur; Jorge E Cortes; Susan O'Brien; Varsha Gandhi; William Plunkett; Anna Byrd; Monica Kwari; Hagop M Kantarjian
Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(16):2755-60.
2010: Elias Jabbour; Deborah Thomas; Jorge Cortes; Hagop M Kantarjian; Susan O'Brien
Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies.
Cancer 2010;116(10):2290-300.
2010: Farhad Ravandi; Jorge E Cortes; Daniel Jones; Stefan Faderl; Guillermo Garcia-Manero; Marina Konopleva; Susan O'Brien; Zeev Estrov; Gautam Borthakur; Deborah Thomas; Sherry R Pierce; Mark Brandt; Anna Byrd; B Nebiyou Bekele; Keith William Pratz; Rajyalakshmi Luthra; Mark Levis; Michael Andreeff; Hagop M Kantarjian
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(11):1856-62.
2010: Roland B Walter; Hagop M Kantarjian; Xuelin Huang; Sherry A Pierce; Zhuoxin Sun; Holly M Gundacker; Farhad Ravandi; Stefan H Faderl; Martin S Tallman; Frederick R Appelbaum; Elihu H Estey
Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(10):1766-71.
2010: Hagop M Kantarjian; Jorge Cortes; Paul La Rosée; Andreas Hochhaus
Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
Cancer 2010;116(6):1419-30.
2010: Robert P Hasserjian; Zhuang Zuo; Christine Garcia; Guilin Tang; Armen Kasyan; Rajyalakshmi Luthra; Lynne V Abruzzo; Hagop M Kantarjian; L Jeffrey Medeiros; Sa A Wang
Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification.
Blood 2010;115(10):1985-92.
2010: Stefan Faderl; Susan O'Brien; Ching-Hon Pui; Wendy Stock; Meir Wetzler; Dieter Hoelzer; Hagop M Kantarjian
Adult acute lymphoblastic leukemia: concepts and strategies.
Cancer 2010;116(5):1165-76.
2010: Hagop M Kantarjian; Deborah Thomas; Farhad Ravandi; Stefan Faderl; Guillermo Garcia-Manero; Jianquin Shan; Sherry Pierce; Jorge Cortes; Susan O'Brien
Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission.
Leukemia & lymphoma 2010;51(3):475-80.
2010: Fabio P S Santos; Hagop M Kantarjian; Nitin Jain; Taghi Manshouri; Deborah A Thomas; Guillermo Garcia-Manero; Debra Kennedy; Zeev Estrov; Jorge Cortes; Srdan Verstovsek
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Blood 2010;115(6):1131-6.
2010: Sameer A Parikh; Hagop M Kantarjian; Mary Ann Richie; Jorge E Cortes; Srdan Verstovsek
Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis.
Leukemia & lymphoma 2010;51(2):269-74.
2010: Hagop M Kantarjian; Harry P Erba; David F Claxton; Martha Arellano; Roger M Lyons; Tibor Kovascovics; Janice Gabrilove; Michael Craig; Dan Douer; Michael Maris; Stephen Petersdorf; Paul J Shami; Andrew M Yeager; Stephen Eckert; Rekha Abichandani; Stefan Faderl
Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(4):549-55.
2010: Gheath Alatrash; Maher Albitar; Susan O'Brien; Xuemei Wang; Taghi Manshouri; Stefan Faderl; Alessandra Ferrajoli; Jan Burger; Guillermo Garcia-Manero; Hagop M Kantarjian; Susan Lerner; Michael J Keating; Jan A Burger
Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).
British journal of haematology 2010;148(3):386-93.
2010: Jorge E Cortes; Michele Baccarani; François Guilhot; Brian J Druker; Susan Branford; Dong-Wook Kim; Fabrizio Pane; Ricardo Pasquini; Stuart L Goldberg; Matt Kalaycio; Beatriz Moiraghi; Jacob M Rowe; Elena Tothova; Carmino De Souza; Marc Rudoltz; Richard Yu; Tillmann Krahnke; Hagop M Kantarjian; Jerald P Radich; Timothy P Hughes
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(3):424-30.
2010: Nikolay D Dimov; L Jeffrey Medeiros; Hagop M Kantarjian; Jorge E Cortes; Kun-Sang Chang; Carlos E Bueso-Ramos; Farhad Ravandi
Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patients.
Cancer 2010;116(2):369-76.
2010: Elias Jabbour; Andreas Hochhaus; Jorge Cortes; P La Rosée; Hagop M Kantarjian
Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.
Leukemia 2010;24(1):6-12.
2009: Deborah A Thomas; Hagop M Kantarjian; Wendy Stock; Leonard T Heffner; Stefan Faderl; Guillermo Garcia-Manero; Alessandra Ferrajoli; William G Wierda; Sherry Pierce; Biao Lu; Steven R Deitcher; Susan O'Brien
Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.
Cancer 2009;115(23):5490-8.
2009: Weina Chen; Sergej Konoplev; L Jeffrey Medeiros; Hartmut Koeppen; Vasiliki Leventaki; Saroj Vadhan-Raj; Dan Jones; Hagop M Kantarjian; Brunangelo Falini; Carlos E Bueso-Ramos
Cuplike nuclei (prominent nuclear invaginations) in acute myeloid leukemia are highly associated with FLT3 internal tandem duplication and NPM1 mutation.
Cancer 2009;115(23):5481-9.
2009: Arturo Vega-Ruiz; Jorge E Cortes; Matjaz Sever; Taghi Manshouri; Alfonso Quintás-Cardama; Rajyalakshmi Luthra; Hagop M Kantarjian; Srdan Verstovsek
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.
Leukemia research 2009;33(11):1481-4.
2009: Sergej Konoplev; Xuelin Huang; Harry A Drabkin; Hartmut Koeppen; Dan Jones; Hagop M Kantarjian; Guillermo Garcia-Manero; Weina Chen; L Jeffrey Medeiros; Carlos E Bueso-Ramos
Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis.
Cancer 2009;115(20):4737-44.
2009: Deborah A Thomas; Susan O'Brien; Hagop M Kantarjian
Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia.
Hematology/oncology clinics of North America 2009;23(5):949-71, v.
2009: Deborah A Thomas; Farhad Ravandi; Michael Keating; Hagop M Kantarjian
Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategy.
Leukemia & lymphoma 2009;50 Suppl 1():27-31.
2009: Jorge E Cortes; Hagop M Kantarjian; Stuart L Goldberg; Bayard L Powell; Francis Giles; Meir Wetzler; Luke Akard; John M Burke; Robert Kerr; Mansoor Saleh; August Salvado; Karen McDougall; Maher Albitar; Jerald P Radich
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4754-9.
2009: Alfonso Quintás-Cardama; Hagop M Kantarjian; Taghi Manshouri; Deborah Thomas; Jorge Cortes; Farhad Ravandi; Guillermo Garcia-Manero; Alessandra Ferrajoli; Carlos E Bueso-Ramos; Srdan Verstovsek
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4760-6.
2009: Ayalew Tefferi; Srdan Verstovsek; Giovanni Barosi; Francesco Passamonti; Gail J Roboz; Heinz Gisslinger; Ronald L Paquette; Francisco Cervantes; Candido E Rivera; H Joachim Deeg; Juergen Thiele; Hans Michael Kvasnicka; James W Vardiman; Yanming Zhang; B Nebiyou Bekele; Ruben A Mesa; Robert P Gale; Hagop M Kantarjian
Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(27):4563-9.
2009: Dushyant Verma; Hagop M Kantarjian; Dan Jones; Rajyalakshmi Luthra; Gautam Borthakur; Srdan Verstovsek; Mary Beth Rios; Jorge Cortes
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
Blood 2009;114(11):2232-5.
2009: Elias Jabbour; Daniel Jones; Hagop M Kantarjian; Susan O'Brien; Constantine Tam; Charles Koller; Jan A Burger; Gautam Borthakur; William G Wierda; Jorge Cortes
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
Blood 2009;114(10):2037-43.
2009: Duncan H Mak; Wendy D Schober; Wenjing Chen; Marina Konopleva; Jorge Cortes; Hagop M Kantarjian; Michael Andreeff; Bing Z Carter
Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
Molecular cancer therapeutics 2009;8(9):2509-16.
2009: Wenyong W Zhang; Jorge E Cortes; Hui Yao; Li Zhang; Neelima G Reddy; Elias Jabbour; Hagop M Kantarjian; Dan Jones
Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(22):3642-9.
2009: Hagop M Kantarjian; Jianqin Shan; Daniel Jones; Susan O'Brien; Mary Beth Rios; Elias Jabbour; Jorge Cortes
Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(22):3659-63.
2009: Omar Abdel-Wahab; Ann Mullally; Cyrus V Hedvat; Guillermo Garcia-Manero; Jay Patel; Martha Wadleigh; Sebastien Malinge; JinJuan Yao; Outi Kilpivaara; Rukhmi Bhat; Kety Huberman; Sabrena Thomas; Igor Dolgalev; Adriana Heguy; Elisabeth Paietta; Michelle M Le Beau; Miloslav Beran; Martin S Tallman; Benjamin L Ebert; Hagop M Kantarjian; Richard M Stone; D Gary Gilliland; John D Crispino; Ross Levine
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
Blood 2009;114(1):144-7.
2009: Alfonso Quintás-Cardama; Jorge E Cortes; Susan O'Brien; Farhad Ravandi; Gautam Borthakur; David Liu; Eric Bleickardt; Tai-Tsang Chen; Hagop M Kantarjian
Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.
Cancer 2009;115(13):2912-21.
2009: Deborah A Thomas; Susan O'Brien; Jeffrey L Jorgensen; Jorge Cortes; Stefan Faderl; Guillermo Garcia-Manero; Srdan Verstovsek; Charles Koller; Sherry Pierce; Yang Huh; William Wierda; Michael J Keating; Hagop M Kantarjian
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.
Blood 2009;113(25):6330-7.
2009: Jean-Pierre J Issa; Hagop M Kantarjian
Targeting DNA methylation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(12):3938-46.
2009: Carmen Fava; Hagop M Kantarjian; Elias Jabbour; Susan O'Brien; Nitin Jain; Mary Beth Rios; Guillermo Garcia-Manero; Farhad Ravandi; Srdan Verstovsek; Gautam Borthakur; Jianqin Shan; Jorge Cortes
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
Blood 2009;113(21):5058-63.
2009: Stefan Faderl; Ashutosh Pal; William G Bornmann; Maher Albitar; David Maxwell; Quin Van; Zhenghong Peng; David Harris; Zhiming Liu; Inbal Hazan-Halevy; Hagop M Kantarjian; Zeev Estrov
Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells.
Cancer research 2009;69(9):3910-7.
2009: Elias Jabbour; Guillermo Garcia-Manero; Ali Taher; Hagop M Kantarjian
Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy.
The oncologist 2009;14(5):489-96.
2009: Hagop M Kantarjian
Introduction: targeting different pathways to prevent tumor cell development.
Seminars in oncology 2009;36(2 Suppl 1):S1-5.
2009: Alfonso Quintás-Cardama; Hagop M Kantarjian; Jorge E Cortes
Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.
Cancer control : journal of the Moffitt Cancer Center 2009;16(2):122-31.
2009: Elias Jabbour; Hagop M Kantarjian; Dan Jones; Jenny Shan; Susan O'Brien; Neeli Reddy; William G Wierda; Stefan Faderl; Guillermo Garcia-Manero; Srdan Verstovsek; Mary Beth Rios; Jorge Cortes
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.
Blood 2009;113(10):2154-60.
2009: Dongjiu Ye; Guillermo Garcia-Manero; Hagop M Kantarjian; Lianchun Xiao; Saroj Vadhan-Raj; Michael H Fernandez; Martin H Nguyen; L Jeffrey Medeiros; Carlos E Bueso-Ramos
Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia.
Journal of hematopathology 2009;2(1):2-8.
2009: Hui Yang; Tapan Kadia; Lianchun Xiao; Carlos E Bueso-Ramos; Koyu Hoshino; Deborah Ann Thomas; Susan O'Brien; Elias Jabbour; Sherry Pierce; Gary Rosner; Hagop M Kantarjian; Guillermo Garcia-Manero
Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia.
Blood 2009;113(9):1892-8.
2009: Apostolia-Maria Tsimberidou; Sijin Wen; Peter McLaughlin; Susan O'Brien; William G Wierda; Susan Lerner; Sara Strom; Emil J Freireich; L Jeffrey Medeiros; Hagop M Kantarjian; Michael J Keating
Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(6):904-10.
2009: Hagop M Kantarjian; Susan O'Brien
Insurance policies in the United States may explain part of the outcome differences of adolescents and young adults with acute lymphoblastic leukemia treated on adult versus pediatric regimens.
Blood 2009;113(8):1861; author reply 1862.
2009: Elias Jabbour; Jorge E Cortes; Hagop M Kantarjian
Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
Mayo Clinic proceedings. Mayo Clinic 2009;84(2):161-9.
2009: Hagop M Kantarjian; Richard A Larson; françois guilhot; Stephen G O'Brien; Manisha Mone; Marc Rudoltz; Tillmann Krahnke; Jorge Cortes; Brian J Druker
Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase.
Cancer 2009;115(3):551-60.
2009: Apostolia-Maria Tsimberidou; Constantine Tam; Lynne V Abruzzo; Susan O'Brien; William G Wierda; Susan Lerner; Hagop M Kantarjian; Michael J Keating
Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia.
Cancer 2009;115(2):373-80.
2009: Effrosyni Apostolidou; Hagop M Kantarjian; Srdan Verstovsek
JAK2 inhibitors: A reality? A hope?
Clinical lymphoma & myeloma 2009;9 Suppl 3():S340-5.
2009: Steven M Kornblau; Raoul Tibes; Yi Hua Qiu; Wenjing Chen; Hagop M Kantarjian; Michael Andreeff; Kevin R Coombes; Gordon B Mills
Functional proteomic profiling of AML predicts response and survival.
Blood 2009;113(1):154-64.
2009: Mikkael A Sekeres; Paul Elson; Matt Kalaycio; Anjali S Advani; Edward A Copelan; Stefan Faderl; Hagop M Kantarjian; Elihu Estey
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients.
Blood 2009;113(1):28-36.
2008: Elias Jabbour; Hagop M Kantarjian; Dan Jones; Neeli Reddy; Susan O'Brien; Guillermo Garcia-Manero; Jan Burger; Jorge Cortes
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
Blood 2008;112(13):4839-42.
2008: Susan O'Brien; Deborah Thomas; Farhad Ravandi; Stefan Faderl; Jorge Cortes; Gautam Borthakur; Sherry Pierce; Guillermo Garcia-Manero; Hagop M Kantarjian
Outcome of adults with acute lymphocytic leukemia after second salvage therapy.
Cancer 2008;113(11):3186-91.
2008: Stefan Faderl; Alessandra Ferrajoli; William G Wierda; Xuelin Huang; Srdan Verstovsek; Farhad Ravandi; Zeev Estrov; Gautam Borthakur; Monica Kwari; Hagop M Kantarjian
Clofarabine combinations as acute myeloid leukemia salvage therapy.
Cancer 2008;113(8):2090-6.
2008: Apostolia-Maria Tsimberidou; Hagop M Kantarjian; Sijin Wen; Michael J Keating; Susan O'Brien; Mark Brandt; Sherry Pierce; Emil J Freireich; L Jeffrey Medeiros; Elihu Estey
Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia.
Cancer 2008;113(6):1370-8.
2008: Dan Jones; Deborah Thomas; C Cameron Yin; Susan O'Brien; Jorge E Cortes; Elias Jabbour; Megan Breeden; Francis Giles; Weiqiang Zhao; Hagop M Kantarjian
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.
Cancer 2008;113(5):985-94.
2008: Constantine S Tam; Roberto M Nussenzveig; Uday Popat; Carlos E Bueso-Ramos; Deborah A Thomas; Jorge A Cortes; Richard E Champlin; Stefan E Ciurea; Taghi Manshouri; Sherry M Pierce; Hagop M Kantarjian; Srdan Verstovsek
The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.
Blood 2008;112(5):1628-37.
2008: Stefan Faderl; Farhad Ravandi; Xuelin Huang; Guillermo Garcia-Manero; Alessandra Ferrajoli; Zeev Estrov; Gautam Borthakur; Srdan Verstovsek; Deborah A Thomas; Monica Kwari; Hagop M Kantarjian
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
Blood 2008;112(5):1638-45.
2008: Heike Kroeger; Jaroslav Jelinek; Marcos R H Estécio; Rong He; Kimie Kondo; Woonbok Chung; LI Zhang; Lanlan Shen; Hagop M Kantarjian; Carlos E Bueso-Ramos; Jean-Pierre J Issa
Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse.
Blood 2008;112(4):1366-73.
2008: Neil P Shah; Hagop M Kantarjian; Dong-Wook Kim; Delphine Réa; Pedro E Dorlhiac-Llacer; Jorge H Milone; Jorge Vela-Ojeda; Richard T Silver; H Jean Khoury; Aude Charbonnier; Nina Khoroshko; Ronald L Paquette; Michael W N Deininger; Robert H Collins; Irma Otero; Timothy Hughes; Eric Bleickardt; Lewis Strauss; Stephen Francis; Andreas Hochhaus
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(19):3204-12.
2008: Taghi Manshouri; Alfonso Quintás-Cardama; Roberto H Nussenzveig; Amos Gaikwad; Zeev Estrov; Josef T Prchal; Jorge E Cortes; Hagop M Kantarjian; Srdan Verstovsek
The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
Cancer science 2008;99(6):1265-73.
2008: Elias Jabbour; Jorge E Cortes; Hagop M Kantarjian
Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications.
Cancer 2008;112(10):2112-8.
2008: Zhifeng Yu; Baohua Sun; Hagop M Kantarjian; Michael J Keating; Hesham M Amin; Xiaoping Sun
Protein expression profiling of cytokines and cytokine receptors on purified chronic lymphocytic leukemia cells from patients with favourable prognostic indicators.
Leukemia & lymphoma 2008;49(4):751-6.
2008: Stefan Faderl; Varsha Gandhi; Hagop M Kantarjian
Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia.
Current opinion in hematology 2008;15(2):101-7.
2008: Elias Jabbour; Hagop M Kantarjian; Charles Koller; Ali Taher
Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes.
Cancer 2008;112(5):1089-95.
2008: Yasuhiro Oki; Jaroslav Jelinek; Lanlan Shen; Hagop M Kantarjian; Jean-Pierre J Issa
Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.
Blood 2008;111(4):2382-4.
2008: Apostolia-Maria Tsimberidou; Hagop M Kantarjian; Sijin Wen; Susan O'Brien; Jorge Cortes; William G Wierda; Charles Koller; Sherry Pierce; Mark Brandt; Emil J Freireich; Michael J Keating; Elihu H Estey
The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(3):721-30.
2008: Guillermo Garcia-Manero; Hui Yang; Carlos E Bueso-Ramos; Alessandra Ferrajoli; Jorge Cortes; William G Wierda; Stefan Faderl; Charles Koller; Gail Morris; Gary Rosner; Andrey Loboda; Valeria R Fantin; Sophia S Randolph; James S Hardwick; John F Reilly; Cong Chen; Justin L Ricker; J Paul Secrist; Victoria M Richon; Stanley R Frankel; Hagop M Kantarjian
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Blood 2008;111(3):1060-6.
2008: Andreas Hochhaus; Brian J Druker; Charles Sawyers; françois guilhot; Charles Alan Schiffer; Jorge Cortes; Dietger Niederwieser; Carlo Gambacorti-Passerini; Carlo Gambacorti; Richard M Stone; John Goldman; Thomas Fischer; Stephen G O'Brien; Jose J Reiffers; Manisha Mone; Tillmann Krahnke; Moshe Talpaz; Hagop M Kantarjian
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.
Blood 2008;111(3):1039-43.
2008: Razelle Kurzrock; Hagop M Kantarjian; Michelle A Blascovich; Cindy Bucher; Srdan Verstovsek; John J Wright; Susan R Pilat; Jorge E Cortes; Elihu H Estey; Francis Giles; Miloslav Beran; Said M Sebti
Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(2):509-14.
2008: Apostolia-Maria Tsimberidou; William G Wierda; William Plunkett; Razelle Kurzrock; Susan O'Brien; Sijin Wen; Alessandra Ferrajoli; Farhad Ravandi-Kashani; Guillermo Garcia-Manero; Zeev Estrov; Thomas Kipps; Jennifer R Brown; Albert Fiorentino; Susan Lerner; Hagop M Kantarjian; Michael J Keating
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(2):196-203.
2008: Elias Jabbour; Jorge E Cortes; Hady Ghanem; Susan O'Brien; Hagop M Kantarjian
Targeted therapy in chronic myeloid leukemia.
Expert review of anticancer therapy 2008;8(1):99-110.
2007: Hagop M Kantarjian
Purine Nucleosidase Phosphorylase (PNP): A novel target in leukemias and lymphomas.
Seminars in oncology 2007;34(6 Suppl 5):S1-2.
2007: Alessandra Ferrajoli; Stefan Faderl; Quin Van; Patricia Koch; David Harris; Zhiming Liu; Inbal Hazan-Halevy; Yongtao Wang; Hagop M Kantarjian; Waldemar Priebe; Zeev Estrov
WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells.
Cancer research 2007;67(23):11291-9.
2007: Hagop M Kantarjian; Francis Giles; Norbert Gattermann; Kapil N Bhalla; Giuliana Alimena; Francesca Palandri; Gert Ossenkoppele; Franck-Emmanuel Nicolini; Stephen G O'Brien; Mark R Litzow; Ravi Bhatia; Francisco Cervantes; Ariful Haque; Yaping Shou; Debra Resta; Aaron Weitzman; Andreas Hochhaus; Philipp le Coutre
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Blood 2007;110(10):3540-6.
2007: Farhad Ravandi; Alan K Burnett; Edward D Agura; Hagop M Kantarjian
Progress in the treatment of acute myeloid leukemia.
Cancer 2007;110(9):1900-10.
2007: Elias Jabbour; Hagop M Kantarjian; Lynne V Abruzzo; Susan O'Brien; Guillermo Garcia-Manero; Srdan Verstovsek; Jianqin Shan; Mary Beth Rios; Jorge Cortes
Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Blood 2007;110(8):2991-5.
2007: Apostolia-Maria Tsimberidou; Sijin Wen; Susan O'Brien; Peter McLaughlin; William G Wierda; Alessandra Ferrajoli; Stefan Faderl; John Manning; Susan Lerner; Chinh V Mai; Alma M Rodriguez; Mark Hess; Kim-Anh Do; Emil J Freireich; Hagop M Kantarjian; L Jeffrey Medeiros; Michael J Keating
Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(29):4648-56.
2007: Hagop M Kantarjian; Sima Jeha; Varsha Gandhi; Michael Miles Wess; Stefan Faderl
Clofarabine: past, present, and future.
Leukemia & lymphoma 2007;48(10):1922-30.
2007: Andres O Soriano; Hui Yang; Stefan Faderl; Zeev Estrov; Francis Giles; Farhad Ravandi; Jorge Cortes; William G Wierda; Souzanne Ouzounian; Andres Quezada; Sherry Pierce; Elihu H Estey; Jean-Pierre J Issa; Hagop M Kantarjian; Guillermo Garcia-Manero
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Blood 2007;110(7):2302-8.
2007: Harrys A Torres; Elizabeth A Aguilera; Gloria N Mattiuzzi; Maria Cabanillas; Nidhi Rohatgi; Carmen A Sepulveda; Hagop M Kantarjian; Ying Jiang; Amar Safdar; Issam I Raad; Roy F Chemaly
Characteristics and outcome of respiratory syncytial virus infection in patients with leukemia.
Haematologica 2007;92(9):1216-23.
2007: Elizabeth R Plimack; Hagop M Kantarjian; Jean-Pierre J Issa
Decitabine and its role in the treatment of hematopoietic malignancies.
Leukemia & lymphoma 2007;48(8):1472-81.
2007: Xiaoping Sun; Wei Zhang; Latha Ramdas; David N Stivers; Daniel M Jones; Hagop M Kantarjian; Elihu H Estey; Saroj Vadhan-Raj; L Jeffrey Medeiros; Carlos E Bueso-Ramos
Comparative analysis of genes regulated in acute myelomonocytic leukemia with and without inv(16)(p13q22) using microarray techniques, real-time PCR, immunohistochemistry, and flow cytometry immunophenotyping.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2007;20(8):811-20.
2007: Elias Jabbour; Jorge E Cortes; Francis Giles; Susan O'Brien; Hagop M Kantarjian
Current and emerging treatment options in chronic myeloid leukemia.
Cancer 2007;109(11):2171-81.
2007: Ahmed Aribi; Hagop M Kantarjian; Elihu H Estey; Charles Koller; Deborah A Thomas; Steven M Kornblau; Stefan Faderl; Nakia M Laddie; Guillermo Garcia-Manero; Jorge E Cortes
Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
Cancer 2007;109(7):1355-9.
2007: Hagop M Kantarjian; Jorge Cortes; françois guilhot; Andreas Hochhaus; Michele Baccarani; Lee Lokey
Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns.
Cancer 2007;109(7):1365-75.
2007: Hagop M Kantarjian; Susan O'Brien; Xuelin Huang; Guillermo Garcia-Manero; Farhad Ravandi; Jorge Cortes; Jianqin Shan; Jan Davisson; Carlos E Bueso-Ramos; Jean-Pierre J Issa
Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.
Cancer 2007;109(6):1133-7.
2007: Hagop M Kantarjian
Therapy for elderly patients with acute myeloid leukemia: a problem in search of solutions.
Cancer 2007;109(6):1007-10.
2007: Andreas Hochhaus; Hagop M Kantarjian; Michele Baccarani; Jeffrey H Lipton; Jane F Apperley; Brian J Druker; Thierry Facon; Stuart L Goldberg; Francisco Cervantes; Dietger Niederwieser; Richard T Silver; Richard M Stone; Timothy P Hughes; Martin C Muller; Rana Ezzeddine; Athena M Countouriotis; Neil P Shah
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
Blood 2007;109(6):2303-9.
2007: Gautam Borthakur; Susan O'Brien; William G Wierda; Deborah A Thomas; Jorge E Cortes; Francis Giles; Hagop M Kantarjian; Susan Lerner; Michael J Keating
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.
British journal of haematology 2007;136(6):800-5.
2007: Yasuhiro Oki; Hagop M Kantarjian; Vazganush Gharibyan; Dan Jones; Susan O'Brien; Srdan Verstovsek; Jorge Cortes; Gail M Morris; Guillermo Garcia-Manero; Jean-Pierre J Issa
Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.
Cancer 2007;109(5):899-906.
2007: Hagop M Kantarjian; Francis Giles; Alfonso Quintás-Cardama; Jorge Cortes
Important therapeutic targets in chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(4):1089-97.
2007: Hagop M Kantarjian
Recent experience with decitabine in MDS.
Clinical advances in hematology & oncology : H&O 2007;5(2):140.
2007: Hagop M Kantarjian; Susan O'Brien; Jianqin Shan; Ahmed Aribi; Guillermo Garcia-Manero; Elias Jabbour; Farhad Ravandi; Jorge Cortes; Jan Davisson; Jean-Pierre J Issa
Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Cancer 2007;109(2):265-73.
2007: Gail J Roboz; Francis Giles; Ellen K Ritchie; Sandra Allen-Bard; Tania J Curcio; Meredith A Wilkes; S Lani Park; Hagop M Kantarjian; Stefan Faderl; Farhad Ravandi; Michael J Kelner; Eric J Feldman
Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(1):10-5.
2007: Xin Han; Guillermo Garcia-Manero; Timothy J McDonnell; Guillermina Lozano; L Jeffrey Medeiros; Lianchun Xiao; Gary Rosner; Martin Nguyen; Michael Fernandez; Yasmine A Valentin-Vega; Juan A Barboza; Daniel M Jones; George Z Rassidakis; Hagop M Kantarjian; Carlos E Bueso-Ramos
HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2007;20(1):54-62.
2007: Jingxuan Pan; Alfonso Quintás-Cardama; Hagop M Kantarjian; Cem Akin; Taghi Manshouri; Peter Lamb; Jorge E Cortes; Ayalew Tefferi; Francis Giles; Srdan Verstovsek
EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
Blood 2007;109(1):315-22.
2007: Stefan Faderl; Alessandra Ferrajoli; David Harris; Quin Van; Hagop M Kantarjian; Zeev Estrov
Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells.
Leukemia research 2007;31(1):91-5.
2006: Hagop M Kantarjian; Moshe Talpaz; Francis Giles; Susan O'Brien; Jorge Cortes
New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.
Annals of internal medicine 2006;145(12):913-23.
2006: Guillermo Garcia-Manero; Hagop M Kantarjian; Blanca Sanchez-Gonzalez; Hui Yang; Gary Rosner; Srdan Verstovsek; Michael Rytting; William G Wierda; Farhad Ravandi; Charles Koller; Lianchun Xiao; Stefan Faderl; Zeev Estrov; Jorge Cortes; Susan O'Brien; Elihu Estey; Carlos E Bueso-Ramos; Jackie Fiorentino; Elias Jabbour; Jean-Pierre J Issa
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
Blood 2006;108(10):3271-9.
2006: Weiqiang Zhao; David F Claxton; L Jeffrey Medeiros; Di Lu; Saroj Vadhan-Raj; Hagop M Kantarjian; Martin H Nguyen; Carlos E Bueso-Ramos
Immunohistochemical analysis of CBFbeta-SMMHC protein reveals a unique nuclear localization in acute myeloid leukemia with inv(16)(p13q22).
The American journal of surgical pathology 2006;30(11):1436-44.
2006: Ricardo H Alvarez; Hagop M Kantarjian; Jorge E Cortes
The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors.
Cancer 2006;107(8):1918-29.
2006: Frederick R Appelbaum; Kenneth J Kopecky; Martin S Tallman; Marilyn L Slovak; Holly Gundacker; Haesook T Kim; Gordon W Dewald; Hagop M Kantarjian; Sherry R Pierce; Elihu H Estey
The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations.
British journal of haematology 2006;135(2):165-73.
2006: Apostolia-Maria Tsimberidou; Susan O'Brien; Hagop M Kantarjian; Charles Koller; Fredrick B Hagemeister; Luis Fayad; Susan Lerner; Carlos E Bueso-Ramos; Michael J Keating
Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience.
Cancer 2006;107(6):1294-302.
2006: Hagop M Kantarjian; Moshe Talpaz; Susan O'Brien; Daniel Jones; Francis Giles; Guillermo Garcia-Manero; Stefan Faderl; Farhad Ravandi; Mary Beth Rios; Jianqin Shan; Jorge Cortes
Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
Blood 2006;108(6):1835-40.
2006: Ricardo H Alvarez; Hagop M Kantarjian; Jorge E Cortes
Biology of platelet-derived growth factor and its involvement in disease.
Mayo Clinic proceedings. Mayo Clinic 2006;81(9):1241-57.
2006: Mihaela Onciu; Ellen Schlette; Yinmei Zhou; Susana C Raimondi; Francis Giles; Hagop M Kantarjian; L Jeffrey Medeiros; Raul C Ribeiro; Ching-Hon Pui; John T Sandlund
Secondary chromosomal abnormalities predict outcome in pediatric and adult high-stage Burkitt lymphoma.
Cancer 2006;107(5):1084-92.
2006: Ayalew Tefferi; Jorge Cortes; Srdan Verstovsek; Ruben A Mesa; Deborah Thomas; Terra L Lasho; William J Hogan; Mark R Litzow; Jacob B Allred; Dan Jones; Catriona Byrne; Jerome B Zeldis; Rhett P Ketterling; Rebecca F McClure; Francis Giles; Hagop M Kantarjian
Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
Blood 2006;108(4):1158-64.
2006: Elias Jabbour; Jorge Cortes; Hagop M Kantarjian; Sergio Giralt; Dan Jones; Roy Jones; Francis Giles; Borje S Andersson; Richard Champlin; Marcos De Lima
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
Blood 2006;108(4):1421-3.
2006: Yasuhiro Oki; Jaroslav Jelinek; Miloslav Beran; Srdan Verstovsek; Hagop M Kantarjian; Jean-Pierre J Issa
Mutations and promoter methylation status of NPM1 in myeloproliferative disorders.
Haematologica 2006;91(8):1147-8.
2006: Charles Koller; B Nebiyou Bekele; Xian Zhou; Charles Park; Zeev Estrov; Susan O'Brien; Michael Keating; Iman Jilani; Francis Giles; Hagop M Kantarjian; Maher Albitar
Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia.
Blood 2006;108(3):1001-6.
2006: Stefan Faderl; Srdan Verstovsek; Jorge Cortes; Farhad Ravandi; Miloslav Beran; Guillermo Garcia-Manero; Alessandra Ferrajoli; Zeev Estrov; Susan O'Brien; Charles Koller; Francis Giles; William G Wierda; Monica Kwari; Hagop M Kantarjian
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.
Blood 2006;108(1):45-51.
2006: Amar Safdar; Gilhen H Rodriguez; Benjamin Lichtiger; Burton F Dickey; Dimitrios P Kontoyiannis; Emil J Freireich; Elizabeth J Shpall; Issam I Raad; Hagop M Kantarjian; Richard E Champlin
Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions.
Cancer 2006;106(12):2664-71.
2006: Farhad Ravandi; Jeffrey L Jorgensen; Susan M O'Brien; Srdan Verstovsek; Charles Koller; Stefan Faderl; Francis Giles; Alessandra Ferrajoli; William G Wierda; Shirley Odinga; Xuelin Huang; Deborah A Thomas; Emil J Freireich; Dan Jones; Michael J Keating; Hagop M Kantarjian
Eradication of minimal residual disease in hairy cell leukemia.
Blood 2006;107(12):4658-62.
2006: Alfonso Quintás-Cardama; Hagop M Kantarjian; Francis Giles; Srdan Verstovsek
Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders.
Seminars in thrombosis and hemostasis 2006;32(4 Pt 2):409-16.
2006: Apostolia-Maria Tsimberidou; Susan O'Brien; Issa Khouri; Francis Giles; Hagop M Kantarjian; Richard Champlin; Sijin Wen; Kim-Anh Do; Susan C Smith; Susan Lerner; Emil J Freireich; Michael J Keating
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(15):2343-51.
2006: Allen S Yang; Ketan Doshi; Sang-Woon Choi; Joel B Mason; Rajan K Mannari; Vazganush Gharybian; Rene Luna; Asif Rashid; Lanlan Shen; Marcos R H Estecio; Hagop M Kantarjian; Guillermo Garcia-Manero; Jean-Pierre J Issa
DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.
Cancer research 2006;66(10):5495-503.
2006: Hagop M Kantarjian; Jorge Cortes
New strategies in chronic myeloid leukemia.
International journal of hematology 2006;83(4):289-93.
2006: Deborah A Thomas; Francis Giles; Maher Albitar; Jorge E Cortes; Srdan Verstovsek; Stefan Faderl; Susan M O'Brien; Guillermo Garcia-Manero; Michael J Keating; Sherry Pierce; Jerome B Zeldis; Hagop M Kantarjian
Thalidomide therapy for myelofibrosis with myeloid metaplasia.
Cancer 2006;106(9):1974-84.
2006: Jorge E Cortes; Moshe Talpaz; Susan O'Brien; Stefan Faderl; Guillermo Garcia-Manero; Alessandra Ferrajoli; Srdan Verstovsek; Mary Beth Rios; Jianqin Shan; Hagop M Kantarjian
Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.
Cancer 2006;106(6):1306-15.
2006: Elias J Jabbour; Elihu Estey; Hagop M Kantarjian
Adult acute myeloid leukemia.
Mayo Clinic proceedings. Mayo Clinic 2006;81(2):247-60.
2006: Apostolia-Maria Tsimberidou; Francis Giles; Elihu Estey; Susan O'Brien; Michael J Keating; Hagop M Kantarjian
The role of gemtuzumab ozogamicin in acute leukaemia therapy.
British journal of haematology 2006;132(4):398-409.
2006: Yasuhiro Oki; Hagop M Kantarjian; Xian Zhou; Jorge Cortes; Stefan Faderl; Srdan Verstovsek; Susan O'Brien; Charles Koller; Miloslav Beran; B Nebiyou Bekele; Sherry Pierce; Deborah Thomas; Farhad Ravandi; William G Wierda; Francis Giles; Alessandra Ferrajoli; Elias Jabbour; Michael J Keating; Carlos E Bueso-Ramos; Elihu Estey; Guillermo Garcia-Manero
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
Blood 2006;107(3):880-4.
2005: Stefan Faderl; Kim-Anh Do; Marcella M Johnson; Michael Keating; Susan O'Brien; Iman Jilani; Alessandra Ferrajoli; Farhad Ravandi-Kashani; Christine Aguilar; Amanda Dey; Deborah A Thomas; Francis Giles; Hagop M Kantarjian; Maher Albitar
Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia.
Blood 2005;106(13):4303-7.
2005: Karen W L Yee; Elias Jabbour; Hagop M Kantarjian; Francis Giles
Clinical experience with decitabine in North American patients with myelodysplastic syndrome.
Annals of hematology 2005;84 Suppl 1():18-24.
2005: Jaroslav Jelinek; Yasuhiro Oki; Vazganush Gharibyan; Carlos E Bueso-Ramos; Josef T Prchal; Srdan Verstovsek; Miloslav Beran; Elihu Estey; Hagop M Kantarjian; Jean-Pierre J Issa
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.
Blood 2005;106(10):3370-3.
2005: Francis Giles; Jorge E Cortes; Hagop M Kantarjian
Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.
Current molecular medicine 2005;5(7):615-23.
2005: Elias J Jabbour; Stefan Faderl; Hagop M Kantarjian
Adult acute lymphoblastic leukemia.
Mayo Clinic proceedings. Mayo Clinic 2005;80(11):1517-27.
2005: H Gao; Bang-Ning Lee; Moshe Talpaz; Nicholas J Donato; Jorge E Cortes; Hagop M Kantarjian; James M Reuben
Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia.
Leukemia 2005;19(11):1905-11.
2005: Karen W L Yee; Anne Hagey; Srdan Verstovsek; Jorge Cortes; Guillermo Garcia-Manero; Susan M O'Brien; Stefan Faderl; Deborah Thomas; William G Wierda; Steven M Kornblau; Alessandra Ferrajoli; Maher Albitar; Evelyn McKeegan; David R Grimm; Toby Mueller; Rhonda R Holley-Shanks; Leonardo Sahelijo; Gary B Gordon; Hagop M Kantarjian; Francis Giles
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(18):6615-24.
2005: Hesham M Amin; Y Yang; Yu Shen; Elihu H Estey; Francis Giles; Sherry A Pierce; Hagop M Kantarjian; Susan M O'Brien; Iman Jilani; Maher Albitar
Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias.
Leukemia 2005;19(9):1567-72.
2005: Hagop M Kantarjian; Carlos E Bueso-Ramos; Moshe Talpaz; Susan O'Brien; Francis Giles; Stefan Faderl; William G Wierda; Mary Beth Rios; Jianqin Shan; Jorge Cortes
Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.
Cancer 2005;104(4):777-80.
2005: Stefan Faderl; Hagop M Kantarjian
Drug insight: emerging new drugs in the treatment of myelodysplastic syndromes.
Nature clinical practice. Oncology 2005;2(7):348-55.
2005: Hagop M Kantarjian; Carlos E Bueso-Ramos; Moshe Talpaz; Susan O'Brien; Francis Giles; Mary Beth Rios; Jianqin Shan; Jorge Cortes
The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy.
Leukemia & lymphoma 2005;46(7):993-7.
2005: Hagop M Kantarjian; Jean-Pierre J Issa
Decitabine dosing schedules.
Seminars in hematology 2005;42(3 Suppl 2):S17-22.
2005: Jean-Pierre J Issa; Hagop M Kantarjian
Introduction: emerging role of epigenetic therapy: focus on decitabine.
Seminars in hematology 2005;42(3 Suppl 2):S1-2.
2005: Jean-Pierre J Issa; Vazganush Gharibyan; Jorge Cortes; Jaroslav Jelinek; Gail Morris; Srdan Verstovsek; Moshe Talpaz; Guillermo Garcia-Manero; Hagop M Kantarjian
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(17):3948-56.
2005: Francis Giles; Hagop M Kantarjian; Jorge E Cortes; Stefan Faderl; Srdan Verstovsek; Deborah Thomas; Guillermo Garcia-Manero; William G Wierda; Alessandra Ferrajoli; Steven M Kornblau; Gloria N Mattiuzzi; Apostolia-Maria Tsimberidou; Maher Albitar; Susan M O'Brien; Elihu Estey
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
Leukemia research 2005;29(6):649-52.
2005: Stefan Faderl; Varsha Gandhi; Michael J Keating; Sima Jeha; William Plunkett; Hagop M Kantarjian
The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog.
Cancer 2005;103(10):1985-95.
2005: Jean-Pierre J Issa; Hagop M Kantarjian; Peter Kirkpatrick
Azacitidine.
Nature reviews. Drug discovery 2005;4(4):275-6.
2005: Ayalew Tefferi; Gordon W Dewald; Mark L Litzow; Jorge Cortes; Michael J Mauro; Moshe Talpaz; Hagop M Kantarjian
Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment.
Mayo Clinic proceedings. Mayo Clinic 2005;80(3):390-402.
2005: Hemantkumar S Patel; Hagop M Kantarjian; Carlos E Bueso-Ramos; L Jeffrey Medeiros; Mohammad A Haidar
Frequent deletions at 12q14.3 chromosomal locus in adult acute lymphoblastic leukemia.
Genes, chromosomes & cancer 2005;42(1):87-94.
2004: Iman Jilani; Michael Keating; Francis Giles; Susan O'Brien; Hagop M Kantarjian; Maher Albitar
Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay.
Leukemia research 2004;28(12):1255-62.
2004: Ray Hachem; Dimitrios P Kontoyiannis; Maha Boktour; Claude Afif; Catherine Cooksley; Gerald P Bodey; Ioannis Chatzinikolaou; Cheryl Perego; Hagop M Kantarjian; Issam I Raad
Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies.
Cancer 2004;101(7):1594-600.
2004: Hagop M Kantarjian; Jorge E Cortes; Susan O'Brien; Rajyalakshmi Luthra; Francis Giles; Srdan Verstovsek; Stefan Faderl; Deborah Thomas; Guillermo Garcia-Manero; Mary Beth Rios; Jianqin Shan; Dan Jones; Moshe Talpaz
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.
Blood 2004;104(7):1979-88.
2004: Maher Albitar; Kim-Anh Do; Marcella M Johnson; Francis Giles; Iman Jilani; Susan O'Brien; Jorge Cortes; Deborah Thomas; Laura Rassenti; Thomas Kipps; Hagop M Kantarjian; Michael Keating
Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies.
Cancer 2004;101(5):999-1008.
2004: Apostolia-Maria Tsimberidou; Elihu Estey; Gary J Whitman; Mark J Dryden; Suresh Ratnam; Sherry Pierce; Stefan Faderl; Francis Giles; Hagop M Kantarjian; Guillermo Garcia-Manero
Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies.
Leukemia research 2004;28(9):991-4.
2004: Stefan Faderl; Hagop M Kantarjian
Novel therapies for myelodysplastic syndromes.
Cancer 2004;101(2):226-41.
2004: Srdan Verstovsek; Francis Giles; Susan O'Brien; Stefan Faderl; Hagop M Kantarjian; Michael J Keating; Maher Albitar
Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia.
Leukemia research 2004;28(7):707-11.
2004: Apostolia-Maria Tsimberidou; Michael J Keating; Francis Giles; William G Wierda; Alessandra Ferrajoli; Susan Lerner; Miloslav Beran; Michael Andreeff; Hagop M Kantarjian; Susan O'Brien
Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
Cancer 2004;100(12):2583-91.
2004: Francis Giles; Jorge E Cortes; Hagop M Kantarjian; Susan M O'Brien
Accelerated and blastic phases of chronic myelogenous leukemia.
Hematology/oncology clinics of North America 2004;18(3):753-74, xii.
2004: Jorge E Cortes; Susan M O'Brien; Francis Giles; Ricardo H Alvarez; Moshe Talpaz; Hagop M Kantarjian
Investigational strategies in chronic myelogenous leukemia.
Hematology/oncology clinics of North America 2004;18(3):619-39, ix.
2004: Francis Giles; Julie M Vose; Kim-Anh Do; Marcella M Johnson; Taghi Manshouri; Gregory Bociek; Philip J Bierman; Susan M O'Brien; Hagop M Kantarjian; James O Armitage; Maher Albitar
Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma.
Leukemia research 2004;28(6):595-604.
2004: Kevin E Sanders; Chul Ha; Jorge E Cortes-Franco; Charles Koller; Hagop M Kantarjian; James D Cox
The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia.
Cancer 2004;100(10):2176-80.
2004: Qinglong Hu; Amanda L Dey; Ying Yang; Yu Shen; Iman Jilani; Elihu H Estey; Hagop M Kantarjian; Francis Giles; Maher Albitar
Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.
Cancer 2004;100(9):1884-91.
2004: Francis Giles; Jorge E Cortes; Hagop M Kantarjian; Susan M O'Brien; Elihu Estey; Miloslav Beran
A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
Leukemia research 2004;28(4):353-7.
2004: Razelle Kurzrock; Maher Albitar; Jorge E Cortes; Elihu H Estey; Stefan Faderl; Guillermo Garcia-Manero; Deborah A Thomas; Francis Giles; Mary Ellen Ryback; Alain Thibault; P De Porre; Hagop M Kantarjian
Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(7):1287-92.
2004: Barbara Scappini; Simona Gatto; Francesco Onida; Clara Ricci; Vladimir Divoky; William G Wierda; Michael Andreeff; Li Dong; Kimberly Hayes; Srdan Verstovsek; Hagop M Kantarjian; Miloslav Beran
Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
Cancer 2004;100(7):1459-71.
2004: Francis Giles; Martin S Tallman; Guillermo Garcia-Manero; Jorge E Cortes; Deborah A Thomas; William G Wierda; Srdan Verstovsek; Marta Hamilton; Emma Barrett; Maher Albitar; Hagop M Kantarjian
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.
Cancer 2004;100(7):1449-58.
2004: Mary Ann Weiser; Maria Cabanillas; Marina Konopleva; Deborah A Thomas; Sherry A Pierce; Carmen P Escalante; Hagop M Kantarjian; Susan M O'Brien
Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
Cancer 2004;100(6):1179-85.
2004: Jean-Pierre J Issa; Guillermo Garcia-Manero; Francis Giles; Rajan Mannari; Deborah Thomas; Stefan Faderl; Emel Bayar; John Lyons; Craig S Rosenfeld; Jorge Cortes; Hagop M Kantarjian
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
Blood 2004;103(5):1635-40.
2004: Carlos E Bueso-Ramos; Frederico C Rocha; Shishir Shishodia; L Jeffrey Medeiros; Hagop M Kantarjian; Saroj Vadhan-Raj; Zeev Estrov; Terry L Smith; Martin H Nguyen; Bharat B Aggarwal
Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia.
Human pathology 2004;35(2):246-53.
2004: Thomas B Sneed; Hagop M Kantarjian; Moshe Talpaz; Susan O'Brien; Mary Beth Rios; B Nebiyou Bekele; Xian Zhou; Debra Resta; William G Wierda; Stefan Faderl; Francis Giles; Jorge E Cortes
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
Cancer 2004;100(1):116-21.
2003: Susan M O'Brien; Hagop M Kantarjian; Deborah A Thomas; Jorge Cortes; Francis Giles; William G Wierda; Charles Koller; Alessandra Ferrajoli; Mary L Browning; Susan Lerner; Maher Albitar; Michael J Keating
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.
Cancer 2003;98(12):2657-63.
2003: Hagop M Kantarjian; Susan O'Brien; Jorge Cortes; Francis Giles; Mary Beth Rios; Jianqin Shan; Stefan Faderl; Guillermo Garcia-Manero; Alessandra Ferrajoli; Srdan Verstovsek; William G Wierda; Michael Keating; Moshe Talpaz
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Cancer 2003;98(12):2636-42.
2003: Razelle Kurzrock; Hagop M Kantarjian; Jorge E Cortes; Neil Singhania; Deborah A Thomas; Edward F Wilson; John J Wright; Emil J Freireich; Moshe Talpaz; Said M Sebti
Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.
Blood 2003;102(13):4527-34.
2003: Bryan T. J. Hennessy; Guillermo Garcia-Manero; Hagop M Kantarjian; Francis Giles
DNA methylation in haematological malignancies: the role of decitabine.
Expert opinion on investigational drugs 2003;12(12):1985-93.
2003: Francis Giles; Julie M Vose; Kim-Anh Do; Marcella M Johnson; Taghi Manshouri; Gregory Bociek; Philip J Bierman; Susan M O'Brien; Michael J Keating; Hagop M Kantarjian; James O Armitage; Maher Albitar
Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease.
British journal of haematology 2003;123(5):850-7.
2003: Apostolia-Maria Tsimberidou; Elihu Estey; Jorge E Cortes; Guillermo Garcia-Manero; Stefan Faderl; Srdan Verstovsek; Deborah A Thomas; Alessandra Ferrajoli; Michael J Keating; Susan O'Brien; Hagop M Kantarjian; Francis Giles
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia.
Cancer chemotherapy and pharmacology 2003;52(6):449-52.
2003: Francis Giles; Eric J Feldman; Gail J Roboz; Richard A Larson; Steven W Mamus; Jorge E Cortes; Srdan Verstovsek; Stefan Faderl; Moshe Talpaz; Miloslav Beran; Maher Albitar; Susan M O'Brien; Hagop M Kantarjian
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.
Leukemia research 2003;27(12):1091-6.
2003: Francis Giles; Paula M Fracasso; Hagop M Kantarjian; Jorge E Cortes; Randy A Brown; Srdan Verstovsek; Yesid Alvarado; Deborah A Thomas; Stefan Faderl; Guillermo Garcia-Manero; Lisa P Wright; Tom Samson; Ann Cahill; Paula Lambert; William Plunkett; Mario Sznol; John F DiPersio; Varsha Gandhi
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.
Leukemia research 2003;27(12):1077-83.
2003: Deborah A Thomas; Susan O'Brien; Carlos E Bueso-Ramos; Stefan Faderl; Michael J Keating; Francis Giles; Jorge Cortes; Hagop M Kantarjian
Rituximab in relapsed or refractory hairy cell leukemia.
Blood 2003;102(12):3906-11.
2003: Allen S Yang; Marcos R H Estecio; Guillermo Garcia-Manero; Hagop M Kantarjian; Jean-Pierre J Issa
Comment on "Chromosomal instability and tumors promoted by DNA hypomethylation" and "Induction of tumors in nice by genomic hypomethylation".
Science (New York, N.Y.) 2003;302(5648):1153; author reply 1153.
2003: Salim Yazji; Francis Giles; Apostolia-Maria Tsimberidou; Elihu H Estey; Hagop M Kantarjian; S A O'Brien; Razelle Kurzrock
Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes.
Leukemia 2003;17(11):2101-6.
2003: Elihu H Estey; Peter F Thall; Xuemei Wang; Srdan Verstovsek; Jorge Cortes; Hagop M Kantarjian
Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML.
Blood 2003;102(9):3097-9.
2003: Apostolia-Maria Tsimberidou; Francis Giles; Hagop M Kantarjian; Michael J Keating; Susan M O'Brien
Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia--long-term follow-up of a monoclonal antibody-based approach to residual disease.
Leukemia & lymphoma 2003;44(10):1719-25.
2003: Stefan Faderl; Sima Jeha; Hagop M Kantarjian
The biology and therapy of adult acute lymphoblastic leukemia.
Cancer 2003;98(7):1337-54.
2003: Jeong N Lee; Francis Giles; Yang O Huh; Taghi Manshouri; Susan O'Brien; Hagop M Kantarjian; Michael J Keating; Maher Albitar
Molecular differences between small and large cells in patients with chronic lymphocytic leukemia.
European journal of haematology 2003;71(4):235-42.
2003: Miloslav Beran; Susan O'Brien; Deborah A Thomas; Hai T Tran; Jorge E Cortes-Franco; Francis Giles; Elihu Estey; Hagop M Kantarjian
Phase I study of oral topotecan in hematological malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(11):4084-91.
2003: Susan O'Brien; Francis Giles; Moshe Talpaz; Jorge Cortes; Mary Beth Rios; Jianqin Shan; Deborah Thomas; Michael Andreeff; Steven M Kornblau; Stefan Faderl; Guillermo Garcia-Manero; Kevin White; Susie Mallard; Emil J Freireich; Hagop M Kantarjian
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
Cancer 2003;98(5):888-93.
2003: Apostolia-Maria Tsimberidou; Dawn E Colburn; Mary Alma Welch; Jorge E Cortes; Srdan Verstovsek; Susan M O'Brien; Maher Albitar; Hagop M Kantarjian; Francis Giles
Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders.
Cancer chemotherapy and pharmacology 2003;52(3):229-34.
2003: Francis Giles; Gary Guangping Shi; Jorge E Cortes; Deborah Thomas; Anna R Keating; Hagop M Kantarjian; Michael J Keating; Susan M O'Brien
Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia.
Cancer chemotherapy and pharmacology 2003;52(3):223-8.
2003: Simona Gatto; Greg Ball; Francesco Onida; Hagop M Kantarjian; Elihu H Estey; Miloslav Beran
Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS).
Blood 2003;102(5):1622-5.
2003: Hesham M Amin; Iman Jilani; Elihu H Estey; Michael J Keating; Amanda L Dey; Taghi Manshouri; Hagop M Kantarjian; Zeev Estrov; Jorge E Cortes; Deborah A Thomas; Francis Giles; Maher Albitar
Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome.
Blood 2003;102(5):1866-8.
2003: Simona Gatto; Barbara Scappini; Lan V Pham; Francesco Onida; Michele Milella; Greg Ball; Clara Ricci; Vladimir Divoky; Srdan Verstovsek; Hagop M Kantarjian; Michael J Keating; Jorge E Cortes-Franco; Miloslav Beran
The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
Haematologica 2003;88(8):853-63.
2003: Hagop M Kantarjian; Susan O'Brien; Jorge Cortes; Francis Giles; Stefan Faderl; Jean-Pierre J Issa; Guillermo Garcia-Manero; Mary Beth Rios; Jianqin Shan; Michael Andreeff; Michael Keating; Moshe Talpaz
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
Cancer 2003;98(3):522-8.
2003: Guillermo Garcia-Manero; Stefan Faderl; Susan O'Brien; Jorge Cortes; Moshe Talpaz; Hagop M Kantarjian
Chronic myelogenous leukemia: a review and update of therapeutic strategies.
Cancer 2003;98(3):437-57.
2003: Zeev Estrov; Shishir Shishodia; Stefan Faderl; David Harris; Quin Van; Hagop M Kantarjian; Moshe Talpaz; Bharat B Aggarwal
Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells.
Blood 2003;102(3):987-95.
2003: Francis Giles; Alison T Stopeck; Lewis R Silverman; Jeffrey E Lancet; Maureen A Cooper; Alison L Hannah; Julie M Cherrington; Anne-Marie O'Farrell; Helene A Yuen; Sharianne G Louie; Weiru Hong; Jorge E Cortes; Srdan Verstovsek; Maher Albitar; Susan M O'Brien; Hagop M Kantarjian; Judith E Karp
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
Blood 2003;102(3):795-801.
2003: Stefan Faderl; David Harris; Quin Van; Hagop M Kantarjian; Moshe Talpaz; Zeev Estrov
Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia.
Blood 2003;102(2):630-7.
2003: Marina Konopleva; Su-Chun Cheng; Jorge E Cortes; Kimberly J Hayes; Sherry A Pierce; Michael Andreeff; Francis Giles; Susan O'Brien; Hagop M Kantarjian; Elihu H Estey
Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts.
Haematologica 2003;88(7):733-6.
2003: Harrys A Torres; Gerald P Bodey; Kenneth V I Rolston; Hagop M Kantarjian; Issam I Raad; Dimitrios P Kontoyiannis
Infections in patients with aplastic anemia: experience at a tertiary care cancer center.
Cancer 2003;98(1):86-93.
2003: Guillermo Garcia-Manero; Moshe Talpaz; Francis Giles; Jorge Cortes; Stefan Faderl; Susan O'Brien; Deborah Thomas; Srdan Verstovsek; Mary Beth Rios; Jianquin Shan; Alessandra Ferrajoli; William G Wierda; Hagop M Kantarjian
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
Cancer 2003;97(12):3010-6.
2003: Apostolia-Maria Tsimberidou; Hagop M Kantarjian; Elihu Estey; Jorge E Cortes; Srdan Verstovsek; Stefan Faderl; D A Thomas; Guillermo Garcia-Manero; Alessandra Ferrajoli; John T Manning; Michael J Keating; Maher Albitar; Susan O'Brien; Francis Giles
Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy.
Leukemia 2003;17(6):1100-3.
2003: Razelle Kurzrock; Hagop M Kantarjian; Brian J Druker; Moshe Talpaz
Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics.
Annals of internal medicine 2003;138(10):819-30.
2003: LanLan Shen; Minoru Toyota; Yutaka Kondo; Toshiro Obata; Sophia Daniel; Sherry Pierce; Kohzoh Imai; Hagop M Kantarjian; Jean-Pierre J Issa; Guillermo Garcia-Manero
Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia.
Blood 2003;101(10):4131-6.
2003: Jorge E Cortes; Moshe Talpaz; Francis Giles; Susan O'Brien; Mary Beth Rios; Jianqin Shan; Guillermo Garcia-Manero; Stefan Faderl; Deborah A Thomas; William G Wierda; Alessandra Ferrajoli; Sima Jeha; Hagop M Kantarjian
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
Blood 2003;101(10):3794-800.
2003: Francis Giles; B Nebiyou Bekele; Susan O'Brien; Jorge E Cortes; Srdan Verstovsek; Maria Balerdi; Marwan Yared; Xian Zhou; Hagop M Kantarjian; Michael J Keating; Peter F Thall; Maher Albitar
A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression.
British journal of haematology 2003;121(4):578-85.
2003: Francis Giles; Hagop M Kantarjian; Jorge E Cortes; Guillermo Garcia-Manero; Srdan Verstovsek; Stefan Faderl; Deborah A Thomas; Alessandra Ferrajoli; Susan O'Brien; J Kyle Wathen; Lian-Chun Xiao; Donald A Berry; Elihu H Estey
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(9):1722-7.
2003: Apostolia-Maria Tsimberidou; Tracey A Waddelow; Hagop M Kantarjian; Maher Albitar; Francis Giles
Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment.
Leukemia research 2003;27(5):375-80.
2003: Stefan Faderl; Deborah A Thomas; Susan O'Brien; Guillermo Garcia-Manero; Hagop M Kantarjian; Francis Giles; Charles Koller; Alessandra Ferrajoli; Srdan Verstovsek; Barbara Pro; Michael Andreeff; Miloslav Beran; Jorge Cortes; William G Wierda; Ngoc Tran; Michael J Keating
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
Blood 2003;101(9):3413-5.
2003: Francis Giles; Maureen A Cooper; Lewis Silverman; Judith E Karp; Jeffrey E Lancet; Maurizio Zangari; Paul J Shami; Khuda Dad Khan; Alison L Hannah; Julie M Cherrington; Deborah A Thomas; Guillermo Garcia-Manero; Maher Albitar; Hagop M Kantarjian; Alison T Stopeck
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
Cancer 2003;97(8):1920-8.
2003: Apostolia-Maria Tsimberidou; Hagop M Kantarjian; Jorge Cortes; Deborah A Thomas; Stefan Faderl; Guillermo Garcia-Manero; Srdan Verstovsek; Alessandra Ferrajoli; William G Wierda; Yesid Alvarado; Susan M O'Brien; Maher Albitar; Michael J Keating; Francis Giles
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Cancer 2003;97(7):1711-20.
2003: Taghi Manshouri; Kim-Anh Do; Xuemei Wang; Francis Giles; Susan M O'Brien; Helene Saffer; Deborah Thomas; Iman Jilani; Hagop M Kantarjian; Michael J Keating; Maher Albitar
Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance.
Blood 2003;101(7):2507-13.
2003: Hagop M Kantarjian; Varsha Gandhi; Peter Kozuch; Stefan Faderl; Francis Giles; Jorge Cortes; Susan O'Brien; Nuhad Ibrahim; Fadlo R Khuri; Min Du; Mary Beth Rios; Sima Jeha; Peter McLaughlin; William Plunkett; Michael Keating
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):1167-73.
2003: Francis Giles; Stefan Faderl; Deborah A Thomas; Jorge E Cortes; Guillermo Garcia-Manero; Dan Douer; Alexandra M Levine; Charles Koller; Sima Jeha; Susan M O'Brien; Elihu H Estey; Hagop M Kantarjian
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):1050-6.
2003: Gloria N Mattiuzzi; Jorge E Cortes; Moshe Talpaz; James M Reuben; Mary Beth Rios; Jianjin Shan; Dimitrios P Kontoyiannis; Francis Giles; Issam Raad; Srdan Verstovsek; Alessandra Ferrajoli; Hagop M Kantarjian
Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(3):976-80.
2003: Stefan Faderl; Reuben Lotan; Hagop M Kantarjian; David Harris; Quin Van; Zeev Estrov
N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL).
Leukemia research 2003;27(3):259-66.
2003: Hagop M Kantarjian; Susan O'Brien; Jorge E Cortes; Jianqin Shan; Francis Giles; Mary Beth Rios; Stefan Faderl; William G Wierda; Alessandra Ferrajoli; Srdan Verstovsek; Michael J Keating; Emil J Freireich; Moshe Talpaz
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.
Cancer 2003;97(4):1033-41.
2003: Guillermo Garcia-Manero; Sima Jeha; Jerry Daniel; Jason Williamson; Maher Albitar; Hagop M Kantarjian; Jean-Pierre J Issa
Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia.
Cancer 2003;97(3):695-702.
2003: Hagop M Kantarjian; Moshe Talpaz; Susan O'Brien; Francis Giles; Guillermo Garcia-Manero; Stefan Faderl; Deborah Thomas; Jianqin Shan; Mary Beth Rios; Jorge Cortes
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.
Blood 2003;101(2):473-5.
2003: Hagop M Kantarjian; Moshe Talpaz; Jorge Cortes; Susan O'Brien; Stefan Faderl; Deborah Thomas; Francis Giles; Mary Beth Rios; Jianqin Shan; Ralph B Arlinghaus
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):160-6.
2003: Hagop M Kantarjian; Jorge E Cortes; Susan O'Brien; Francis Giles; Guillermo Garcia-Manero; Stefan Faderl; Deborah Thomas; Sima Jeha; Mary Beth Rios; Laurie Letvak; Kathy Bochinski; Ralph B Arlinghaus; Moshe Talpaz
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses.
Blood 2003;101(1):97-100.
2002: Deborah A Thomas; Jorge Cortes; Hagop M Kantarjian
New agents in the treatment of acute lymphocytic leukaemia.
Best practice & research. Clinical haematology 2002;15(4):771-90.
2002: Clara Ricci; Barbara Scappini; Vladimir Divoky; Simona Gatto; Francesco Onida; Srdan Verstovsek; Hagop M Kantarjian; Miloslav Beran
Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line.
Cancer research 2002;62(21):5995-8.
2002: Alvaro Aguayo; Hagop M Kantarjian; Elihu H Estey; Francis Giles; Srdan Verstovsek; Taghi Manshouri; Christy Gidel; Susan O'Brien; Michael J Keating; Maher Albitar
Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
Cancer 2002;95(9):1923-30.
2002: Francesco Onida; Greg Ball; Hagop M Kantarjian; Terry L Smith; Armand B. Glassman; Maher Albitar; Barbara Scappini; Mary Beth Rios; Michael J Keating; Miloslav Beran
Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia.
Cancer 2002;95(8):1673-84.
2002: Francis Giles; Hagop M Kantarjian; B Nebiyou Bekele; Jorge E Cortes; Stefan Faderl; Deborah A Thomas; Taghi Manshouri; Anna Rogers; Michael J Keating; Moshe Talpaz; Susan O'Brien; Maher Albitar
Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival.
British journal of haematology 2002;119(1):38-45.
2002: Hagop M Kantarjian; Susan O'Brien; Jorge E Cortes; Sergio Giralt; Mary Beth Rios; Jianqin Shan; Francis Giles; Deborah A Thomas; Stefan Faderl; Marcos De Lima; Guillermo Garcia-Manero; Richard Champlin; Ralph B Arlinghaus; Moshe Talpaz
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.
Blood 2002;100(5):1590-5.
2002: Bita Esmaeli; Victor G Prieto; Charles E Butler; Stella K Kim; M Amir Ahmadi; Hagop M Kantarjian; Moshe Talpaz
Severe periorbital edema secondary to STI571 (Gleevec).
Cancer 2002;95(4):881-7.
2002: Guillermo Garcia-Manero; Stefan Faderl; Francis Giles; Deborah Thomas; Jorge Cortes; Susan O'Brien; Jan Davis; Hagop M Kantarjian; Elihu Estey
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
Haematologica 2002;87(8):804-7.
2002: Maher Albitar; Taghi Manshouri; Yu Shen; Diane Liu; Miloslav Beran; Hagop M Kantarjian; Anna Rogers; Iman Jilani; Chung-Wu Lin; Sherry Pierce; Emil J Freireich; Elihu H Estey
Myelodysplastic syndrome is not merely "preleukemia".
Blood 2002;100(3):791-8.
2002: Hagop M Kantarjian; Jorge E Cortes; Jacob M Rowe; Razelle Kurzrock
Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies.
Seminars in hematology 2002;39(3 Suppl 2):36-8.
2002: Jorge E Cortes; Razelle Kurzrock; Hagop M Kantarjian
Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies.
Seminars in hematology 2002;39(3 Suppl 2):26-30.
2002: Guillermo Garcia-Manero; Jerry Daniel; Terry L Smith; Steven M Kornblau; Ming-Sheng Lee; Hagop M Kantarjian; Jean-Pierre J Issa
DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2217-24.
2002: Hagop M Kantarjian; Moshe Talpaz; Susan O'Brien; Terry L Smith; Francis Giles; Stefan Faderl; Deborah A Thomas; Guillermo Garcia-Manero; Jean-Pierre J Issa; Michael Andreeff; Steven M Kornblau; Charles Koller; Miloslav Beran; Michael Keating; Mary Beth Rios; Jianqin Shan; Debra Resta; Renaud Capdeville; Kimberly Hayes; Maher Albitar; Emil J Freireich; Jorge E Cortes
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2177-87.
2002: Hagop M Kantarjian; Susan O'Brien; Jorge E Cortes; Terry L Smith; Mary Beth Rios; Jianqin Shan; Ying Yang; Francis Giles; Deborah A Thomas; Stefan Faderl; Guillermo Garcia-Manero; Sima Jeha; William G Wierda; Jean-Pierre J Issa; Steven M Kornblau; Michael Keating; Debra Resta; Renaud Capdeville; Moshe Talpaz
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2167-76.
2002: Francis Giles; Jorge E Cortes; Deborah A Thomas; Guillermo Garcia-Manero; Stefan Faderl; Sima Jeha; Robert L De Jager; Hagop M Kantarjian
Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2134-41.
2002: Farhad Ravandi; Jorge Cortes; Zeev Estrov; Deborah Thomas; Francis Giles; Yang O Huh; Sherry Pierce; Susan O'Brien; Stefan Faderl; Hagop M Kantarjian
CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia.
Leukemia research 2002;26(7):643-9.
2002: Elihu H Estey; Peter F Thall; Francis Giles; Xue-Mei Wang; Jorge E Cortes; Miloslav Beran; Sherry A Pierce; Deborah A Thomas; Hagop M Kantarjian
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside.
Blood 2002;99(12):4343-9.
2002: Yesid Alvarado; Hagop M Kantarjian; Jorge E Cortes; Effrosyni Apostolidou; Carol Bivins; Francis Giles
Troxacitabine activity in extramedullary myeloid leukemia.
Hematology (Amsterdam, Netherlands) 2002;7(3):179-85.
2002: Stefan Faderl; Guillermo Garcia-Manero; Deborah A Thomas; Hagop M Kantarjian
Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives.
Reviews in clinical and experimental hematology 2002;6(2):142-60; discussion 200-2.
2002: Guillermo Garcia-Manero; Carlos E Bueso-Ramos; Jerry Daniel; Jason Williamson; Hagop M Kantarjian; Jean-Pierre J Issa
DNA methylation patterns at relapse in adult acute lymphocytic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(6):1897-903.
2002: Stefan Faderl; Peter F Thall; Hagop M Kantarjian; Zeev Estrov
Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission.
British journal of haematology 2002;117(4):869-74.
2002: Stefan Faderl; Michael J Keating; Kim-Anh Do; S-Y Liang; Hagop M Kantarjian; Susan O'Brien; Guillermo Garcia-Manero; Taghi Manshouri; Maher Albitar
Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL).
Leukemia 2002;16(6):1045-52.
2002: Elihu H Estey; Francis Giles; Miloslav Beran; Susan O'Brien; Sherry A Pierce; Stefan Faderl; Jorge E Cortes; Hagop M Kantarjian
Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia.
Blood 2002;99(11):4222-4.
2002: Bouthaina S Dabaja; Chul Ha; Deborah A Thomas; Richard B Wilder; Ramesh Gopal; Jorge Cortes; Carlos E Bueso-Ramos; Mark A Hess; James D Cox; Hagop M Kantarjian
The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma.
Cancer 2002;94(10):2738-44.
2002: Barbara Scappini; Francesco Onida; Hagop M Kantarjian; Li Dong; Srdan Verstovsek; Michael J Keating; Miloslav Beran
In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
Cancer 2002;94(10):2653-62.
2002: Hagop M Kantarjian
Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(10):2415-6.
2002: Hagop M Kantarjian; Jorge Cortes; Susan O'Brien; Francis Giles; Maher Albitar; Mary Beth Rios; Jianqin Shan; Stefan Faderl; Guillermo Garcia-Manero; Deborah A Thomas; Debra Resta; Moshe Talpaz
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
Blood 2002;99(10):3547-53.
2002: Apostolia-Maria Tsimberidou; Susan M O'Brien; Jorge E Cortes; Stefan Faderl; Michael Andreeff; Hagop M Kantarjian; Michael J Keating; Francis Giles
Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders.
Leukemia & lymphoma 2002;43(4):767-72.
2002: Guillermo Garcia-Manero; Moshe Talpaz; Hagop M Kantarjian
Current therapy of chronic myelogenous leukemia.
Internal medicine (Tokyo, Japan) 2002;41(4):254-64.
2002: Susan O'Brien; Moshe Talpaz; Jorge Cortes; Jianqin Shan; Francis Giles; Stefan Faderl; Deborah Thomas; Guillermo Garcia-Manero; Susie Mallard; Mary Beth; Charles Koller; Steven M Kornblau; Michael Andreeff; Anthony J Murgo; Michael Keating; Hagop M Kantarjian
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
Cancer 2002;94(7):2024-32.
2002: Moshe Talpaz; Richard T Silver; Brian J Druker; John M Goldman; Carlo Gambacorti-Passerini; françois guilhot; Charles Alan Schiffer; Thomas Fischer; Michael W N Deininger; Anne L Lennard; Andreas Hochhaus; Oliver G Ottmann; Alois Gratwohl; Michele Baccarani; Richard Stone; Sante Tura; Francois-Xavier Mahon; Sofia Fernandes-Reese; Insa Gathmann; Renaud Capdeville; Hagop M Kantarjian; Charles L Sawyers
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Blood 2002;99(6):1928-37.
2002: Francis Giles; Guillermo Garcia-Manero; Jorge E Cortes; Sharyn D Baker; Carole B Miller; Susan M O'Brien; Deborah A Thomas; Michael Andreeff; Carol Bivins; Jacques Jolivet; Hagop M Kantarjian
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(3):656-64.
2002: Francesco Onida; Hagop M Kantarjian; Terry L Smith; Greg Ball; Michael J Keating; Elihu H Estey; Armand B. Glassman; Maher Albitar; Monica Kwari; Miloslav Beran
Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.
Blood 2002;99(3):840-9.
2002: Mary Ann Weiser; Susan O'Brien; Deborah A Thomas; Sherry A Pierce; Tony P Lam; Hagop M Kantarjian
Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen.
Cancer 2002;94(2):285-91.
2002: Francis Giles; Armand Keating; Anthony H Goldstone; Irit Avivi; Cheryl L Willman; Hagop M Kantarjian
Acute myeloid leukemia.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2002;():73-110.
2001: Elihu H Estey; Peter F Thall; Jorge E Cortes; Francis Giles; Susan O'Brien; Sherry A Pierce; Xuemei Wang; Hagop M Kantarjian; Miloslav Beran
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
Blood 2001;98(13):3575-83.
2001: Barbara Scappini; Francesco Onida; Hagop M Kantarjian; Li Dong; Srdan Verstovsek; Michael J Keating; Miloslav Beran
Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12):3884-93.
2001: Hagop M Kantarjian; Jianqin Shan; Terry Smith; Moshe Talpaz; Peter Kozuch; Mary Beth Rios; Jorge Cortes; Francis Giles; Susan O'Brien
Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase.
Cancer 2001;92(10):2501-7.
2001: Stefan Faderl; Zeev Estrov; Hagop M Kantarjian; David Harris; Quin Van; Izabela Fokt; Teresa Przewloka; C Godlewski; Jan Woynarowski; Waldemar Priebe
WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity.
Anticancer research 2001;21(6A):3777-84.
2001: Hagop M Kantarjian; Moshe Talpaz
Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias.
Seminars in oncology 2001;28(5 Suppl 17):9-18.
2001: Maher Albitar; Taghi Manshouri; Christy Gidel; Carlo M Croce; Steven M Kornblau; Sherry Pierce; Hagop M Kantarjian
Clinical significance of fragile histidine triad gene expression in adult acute lymphoblastic leukemia.
Leukemia research 2001;25(10):859-64.
2001: Hagop M Kantarjian; Moshe Talpaz; V Santini; Anthony J Murgo; B Cheson; Susan M O'Brien
Homoharringtonine: history, current research, and future direction.
Cancer 2001;92(6):1591-605.
2001: Moshe Talpaz; Susan O'Brien; E Rose; S Gupta; Jianqin Shan; Jorge Cortes; Francis Giles; Stefan Faderl; Hagop M Kantarjian
Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.
Blood 2001;98(6):1708-13.
2001: R Aboul-Nasr; Susan O'Brien; Emil J Freireich; C F Ginsberg; Hagop M Kantarjian; Charles Koller; Michael J Keating; Maher Albitar
"T-cell-rich B-cell lymphoproliferative disorder" of the bone marrow.
Leukemia & lymphoma 2001;42(5):1023-31.
2001: Francis Giles; Hagop M Kantarjian; Steven M Kornblau; Deborah A Thomas; Guillermo Garcia-Manero; Tracey A Waddelow; Cynthia L David; Alexandria Phan; Dawn E Colburn; Asif Rashid; Elihu H Estey
Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation.
Cancer 2001;92(2):406-13.
2001: Bouthaina S Dabaja; Susan M O'Brien; Hagop M Kantarjian; Jorge E Cortes; Deborah A Thomas; Maher Albitar; E S Schlette; Stefan Faderl; Andreas H Sarris; Michael J Keating; Francis Giles
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome.
Leukemia & lymphoma 2001;42(3):329-37.
2001: S Ibrahim; Michael Keating; Kim-Anh Do; Susan O'Brien; Yang O Huh; Iman Jilani; Susan Lerner; Hagop M Kantarjian; Maher Albitar
CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia.
Blood 2001;98(1):181-6.
2001: Francis Giles; Yu Shen; Hagop M Kantarjian; Martin Korbling; Susan O'Brien; Paolo Anderlini; Michele Donato; Sherry Pierce; Michael J Keating; Emil J Freireich; Elihu Estey
Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival.
Leukemia & lymphoma 2001;42(1-2):67-73.
2001: Farhad Ravandi; Hagop M Kantarjian; Moshe Talpaz; Susan O'Brien; Stefan Faderl; Francis Giles; Deborah Thomas; Jorge Cortes; Michael Andreeff; Zeev Estrov; Mary Beth Rios; Maher Albitar
Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance.
Cancer 2001;91(11):1964-72.
2001: Farhad Ravandi; Kimberly Hayes; Jorge Cortes; Maher Albitar; Armand B. Glassman; Moshe Talpaz; Hagop M Kantarjian
Translocation t(17;18)(q10;q10): a new nonrandom chromosomal translocation of clonal evolution in chronic myeloid leukemia.
Cancer 2001;91(9):1704-8.
2001: Alessandra Ferrajoli; Taghi Manshouri; Zeev Estrov; Michael J Keating; Susan O'Brien; Susan Lerner; Miloslav Beran; Hagop M Kantarjian; Emil J Freireich; Maher Albitar
High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(4):795-9.
2001: Susan M O'Brien; Hagop M Kantarjian; Jorge Cortes; Miloslav Beran; Charles Koller; Francis Giles; Susan Lerner; Michael Keating
Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1414-20.
2001: R V Fleming; Hagop M Kantarjian; Rola Husni; Kenneth Rolston; J Lim; Issam Raad; Sherry Pierce; Jorge Cortes; Elihu Estey
Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia.
Leukemia & lymphoma 2001;40(5-6):511-20.
2001: Deborah A Thomas; Hagop M Kantarjian
Lymphoblastic lymphoma.
Hematology/oncology clinics of North America 2001;15(1):51-95, vi.
2001: Hagop M Kantarjian
Adult acute lymphocytic leukemia. Future research directions.
Hematology/oncology clinics of North America 2001;15(1):207-11, viii.
2001: Francis Giles; Jorge E Cortes; Sharyn D Baker; Deborah A Thomas; Susan O'Brien; Terry L Smith; Miloslav Beran; Carol Bivins; J Jolivet; Hagop M Kantarjian
Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(3):762-71.
2001: Stefan Faderl; Christy Gidel; Hagop M Kantarjian; Taghi Manshouri; Michael Keating; Maher Albitar
Loss of heterozygosity on chromosome 5 in adults with acute lymphoblastic leukemia.
Leukemia research 2001;25(1):39-43.
2000: Guillermo Garcia-Manero; Hagop M Kantarjian
The hyper-CVAD regimen in adult acute lymphocytic leukemia.
Hematology/oncology clinics of North America 2000;14(6):1381-96, x-xi.
2000: Hagop M Kantarjian
Adult acute lymphocytic leukemia. Introduction and questions related to current programs.
Hematology/oncology clinics of North America 2000;14(6):1205-8, VII.
2000: Stefan Faderl; Hagop M Kantarjian; Moshe Talpaz; Zeev Estrov
Clinical significance of minimal residual disease in leukemia.
International journal of oncology 2000;17(6):1277-87.
2000: Nizar M Tannir; Moshe Talpaz; H Ghazal; S Proothi; Hagop M Kantarjian
Acute pancreatitis associated with interferon alpha therapy for chronic myelogenous leukemia.
Leukemia & lymphoma 2000;39(5-6):647-50.
2000: Deborah A Thomas; Hagop M Kantarjian
Current role of thalidomide in cancer treatment.
Current opinion in oncology 2000;12(6):564-73.
2000: S Ibrahim; Elihu H Estey; Sherry Pierce; Armand B. Glassman; Michael Keating; Susan O'Brien; Hagop M Kantarjian; Maher Albitar
11q23 abnormalities in patients with acute myelogenous leukemia and myelodysplastic syndrome as detected by molecular and cytogenetic analyses.
American journal of clinical pathology 2000;114(5):793-7.
2000: Stefan Faderl; Hagop M Kantarjian; Elihu Estey; Taghi Manshouri; C Y Chan; A Rahman Elsaied; Steven M Kornblau; Jorge Cortes; Deborah A Thomas; Sherry Pierce; Michael J Keating; Zeev Estrov; Maher Albitar
The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia.
Cancer 2000;89(9):1976-82.
2000: Hagop M Kantarjian; Francis Giles; Susan O'Brien; Sergio Giralt; Moshe Talpaz
Therapeutic choices in younger patients with chronic myelogenous leukemia.
Cancer 2000;89(8):1647-58.
2000: Hagop M Kantarjian; Moshe Talpaz; Terry L Smith; Jorge Cortes; Francis Giles; Mary Beth Rios; Susie Mallard; James L Gajewski; Anthony J Murgo; B Cheson; Susan O'Brien
Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(20):3513-21.
2000: S Faderl; Hagop M Kantarjian; Moshe Talpaz; Susan O'Brien
New treatment approaches for chronic myelogenous leukemia.
Seminars in oncology 2000;27(5):578-86.
2000: Jorge Romaguera; Issa F Khouri; Hagop M Kantarjian; Fredrick B Hagemeister; Maria A Rodriguez; Peter McLaughlin; Andreas H Sarris; Anas Younes; Jose Rodriguez; Fernando Cabanillas
Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients.
Leukemia & lymphoma 2000;39(1-2):77-85.
2000: James M Reuben; Bang-Ning Lee; H Johnson; Herbert A Fritsche; Hagop M Kantarjian; Moshe Talpaz
Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(5):1671-7.
2000: Yang O Huh; Terry L Smith; P Collins; Carlos E Bueso-Ramos; Maher Albitar; Hagop M Kantarjian; Sherry A Pierce; Emil J Freireich
Terminal deoxynucleotidyl transferase expression in acute myelogenous leukemia and myelodysplasia as determined by flow cytometry.
Leukemia & lymphoma 2000;37(3-4):319-31.
2000: Francis Giles; G C Wong; S J Clark; Sherry Pierce; Hagop M Kantarjian; Michael J Keating
Oral idarubicin in patients with late chronic phase chronic myelogenous leukemia or chronic myelomonocytic leukemia.
Leukemia & lymphoma 2000;37(1-2):87-95.
2000: Mohammad A Haidar; Taghi Manshouri; Michael J Keating; Hagop M Kantarjian; Emil J Freireich; Kapil Mehta; Maher Albitar
Downregulation of the p53 tumor suppressor gene and upregulation of the bcl-2 gene in retinoic acid receptor alpha-deficient transgenic mice.
International journal of oncology 2000;16(3):561-5.
2000: Hagop M Kantarjian; Susan O'Brien; Terry L Smith; Jorge Cortes; Francis Giles; Miloslav Beran; Sherry Pierce; Yang Huh; Michael Andreeff; Charles Koller; Chul Ha; Michael J Keating; S Murphy; Emil J Freireich
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(3):547-61.
2000: Miloslav Beran; Hagop M Kantarjian
Topotecan (hycamptin) and topotecan-containing regimens in the treatment of hematologic malignancies.
Annals of the New York Academy of Sciences 2000;922():247-59.
2000: Stefan Faderl; Hagop M Kantarjian; Deborah A Thomas; Jorge Cortes; Francis Giles; Sherry Pierce; Maher Albitar; Zeev Estrov
Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Leukemia & lymphoma 2000;36(3-4):263-73.
1999: S Sacchi; Hagop M Kantarjian; Susan O'Brien; Jorge Cortes; Mary Beth Rios; Francis Giles; Miloslav Beran; Charles Koller; Michael J Keating; Moshe Talpaz
Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.
Cancer 1999;86(12):2632-41.
1999: Hagop M Kantarjian; Moshe Talpaz; Susan O'Brien; T Manshouri; Jorge Cortes; Francis Giles; Mary Beth Rios; C M Croce; Maher Albitar
Significance of FHIT expression in chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):4059-64.
1999: Stefan Faderl; Peter F Thall; Hagop M Kantarjian; Moshe Talpaz; David Harris; Quin Van; Miloslav Beran; Steven M Kornblau; Sherry Pierce; Zeev Estrov
Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):4041-7.
1999: Francis Giles; Susan M O'Brien; V Santini; Varsha Gandhi; William Plunkett; John F Seymour; LE Robertson; Hagop M Kantarjian; Michael J Keating
Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study.
Leukemia & lymphoma 1999;36(1-2):57-65.
1999: Charles Koller; Hagop M Kantarjian; Eric J Feldman; Susan O'Brien; Mary Beth Rios; Elihu Estey; Michael Keating
A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
Cancer 1999;86(11):2246-51.
1999: Farhad Ravandi; Jorge Cortes; Maher Albitar; Ralph B Arlinghaus; J Qiang Guo; Moshe Talpaz; Hagop M Kantarjian
Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance.
British journal of haematology 1999;107(3):581-6.
1999: S Sacchi; Hagop M Kantarjian; E J Freireich; Susan O'Brien; Jorge Cortes; Mary Beth Rios; S Kornblau; Francis Giles; Charles Koller; James L Gajewski; Moshe Talpaz
Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia.
Leukemia & lymphoma 1999;35(5-6):483-9.
1999: Zeev Estrov; S K Manna; David Harris; Quin Van; Elihu H Estey; Hagop M Kantarjian; Moshe Talpaz; Bharat B Aggarwal
Phenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells.
Blood 1999;94(8):2844-53.
1999: Stefan Faderl; Zeev Estrov; Hagop M Kantarjian; Deborah Thomas; Jorge Cortes; Taghi Manshouri; C C Chan; K J Hays; Sherry Pierce; Maher Albitar
The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes p15(INK4b)/p16(INK4a)/p14(ARF) in patients with acute lymphoblastic leukemia.
Cytokines, cellular & molecular therapy 1999;5(3):159-63.
1999: Francis Giles; Hagop M Kantarjian; Jorge Cortes; Deborah A Thomas; Moshe Talpaz; Taghi Manshouri; Maher Albitar
Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance.
Cancer 1999;86(5):805-13.
1999: Stefan Faderl; Moshe Talpaz; Zeev Estrov; Hagop M Kantarjian
Chronic myelogenous leukemia: biology and therapy.
Annals of internal medicine 1999;131(3):207-19.
1999: D Seong; Hagop M Kantarjian; Maher Albitar; Ralph B Arlinghaus; Jingping Xu; Moshe Talpaz; Mary Beth Rios; Jie Qiang Guo; Susan O'Brien; Michael J Siciliano
Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(8):955-9.
1999: Stefan Faderl; Moshe Talpaz; Zeev Estrov; Susan O'Brien; Razelle Kurzrock; Hagop M Kantarjian
The biology of chronic myeloid leukemia.
The New England journal of medicine 1999;341(3):164-72.
1999: Stefan Faderl; Hagop M Kantarjian; Taghi Manshouri; C Y Chan; Sherry Pierce; K J Hays; Jorge Cortes; Deborah Thomas; Zeev Estrov; Maher Albitar
The prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(7):1855-61.
1999: Farhad Ravandi-Kashani; Jorge Cortes; Moshe Talpaz; Hagop M Kantarjian
Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect?
Cancer 1999;85(12):2583-8.
1999: R Aboul-Nasr; Elihu H Estey; Hagop M Kantarjian; Emil J Freireich; Michael Andreeff; B J Johnson; Maher Albitar
Comparison of touch imprints with aspirate smears for evaluating bone marrow specimens.
American journal of clinical pathology 1999;111(6):753-8.
1999: R Weinkauff; Elihu H Estey; P Starostik; Kimberly Hayes; Yang O Huh; Cheryl Hirsch-Ginsberg; Michael Andreeff; Michael Keating; Hagop M Kantarjian; Emil J Freireich; Maher Albitar
Use of peripheral blood blasts vs bone marrow blasts for diagnosis of acute leukemia.
American journal of clinical pathology 1999;111(6):733-40.
1999: B S Dabaja; Stefan Faderl; Deborah Thomas; Jorge Cortes; Susan O'Brien; F Nasr; Sherry Pierce; Kimberly Hayes; Armand B. Glassman; Michael Keating; Hagop M Kantarjian
Deletions and losses in chromosomes 5 or 7 in adult acute lymphocytic leukemia: incidence, associations and implications.
Leukemia 1999;13(6):869-72.
1999: Stefan Faderl; Moshe Talpaz; Hagop M Kantarjian; Zeev Estrov
Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?
Blood 1999;93(9):2755-9.
1999: Jorge E Cortes; Hagop M Kantarjian; Susan O'Brien; Francis Giles; Michael J Keating; Emil J Freireich; Elihu H Estey
A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission.
Cancer 1999;85(7):1506-13.
1999: Stefan Faderl; Hagop M Kantarjian; Moshe Talpaz
Chronic myelogenous leukemia: update on biology and treatment.
Oncology (Williston Park, N.Y.) 1999;13(2):169-80; discussion 181, 184.
1999: Hagop M Kantarjian; Susan O'Brien; Terry L Smith; Mary Beth Rios; Jorge Cortes; Miloslav Beran; Charles Koller; Francis Giles; Michael Andreeff; Steven M Kornblau; Sergio Giralt; Michael J Keating; Moshe Talpaz
Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):284-92.
1999: Alvaro Aguayo; Jorge E Cortes; Hagop M Kantarjian; Miloslav Beran; Varsha Gandhi; William Plunkett; Joanne Kurtzberg; Michael J Keating
Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature.
Cancer 1999;85(1):58-64.
1998: Miloslav Beran; Elihu Estey; Susan M O'Brien; Francis Giles; Charles Koller; Steven M Kornblau; Michael Keating; Hagop M Kantarjian
Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Leukemia & lymphoma 1998;31(5-6):521-31.
1998: Zeev Estrov; Peter F Thall; Moshe Talpaz; Elihu H Estey; Hagop M Kantarjian; Michael Andreeff; David Harris; Quin Van; M Walterscheid; Steven M Kornblau
Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia.
Blood 1998;92(9):3090-7.
1998: Stefan Faderl; Hagop M Kantarjian; Moshe Talpaz; Zeev Estrov
Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia.
Blood 1998;91(11):3995-4019.
1998: TM Schenk; Afsaneh Keyhani; S Bottcher; Kay-Oliver Kliche; AM Goodacre; Jie Qiang Guo; Ralph B Arlinghaus; Hagop M Kantarjian; Michael Andreeff
Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia.
Leukemia 1998;12(5):666-74.
1998: D Seong; Peter F Thall; Hagop M Kantarjian; Moshe Talpaz; J Swantkowski; Jingping Xu; Yu Shen; Armand B. Glassman; Louis S Ramagli; Michael J Siciliano
Philadelphia chromosome-positive myeloid cells in the peripheral blood of chronic myelogenous leukemia patients: comparison with the frequency detected in cycling cells of the bone marrow.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(4):861-7.
1998: S Sacchi; Hagop M Kantarjian; Terry L Smith; Susan O'Brien; Sherry Pierce; Steven M Kornblau; Miloslav Beran; Michael J Keating; Moshe Talpaz
Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(3):882-9.
1998: Hagop M Kantarjian; Francis Giles; Susan M O'Brien; Moshe Talpaz
Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy.
Hematology/oncology clinics of North America 1998;12(1):31-80.
1997: Hagop M Kantarjian; Moshe Talpaz; Susan O'Brien; Razelle Kurzrock; Jordan U Gutterman; Michael J Keating; K B McCredie; Emil J Freireich
Chronic myelogenous leukemia--progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(12 Pt 2):2723-33.
1997: Charles Koller; Hagop M Kantarjian; Deborah Thomas; Susan O'Brien; Mary Beth Rios; Steven M Kornblau; S Murphy; Michael Keating
The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia.
Leukemia 1997;11(12):2039-44.
1997: Hagop M Kantarjian; S M O'Brien; M Keating; Miloslav Beran; E Estey; Sergio Giralt; S Kornblau; Mary Beth Rios; D de Vos; Moshe Talpaz
Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia.
Leukemia 1997;11(10):1617-20.
1997: S Sacchi; Hagop M Kantarjian; Susan O'Brien; Miloslav Beran; Charles Koller; Sherry Pierce; S Kornblau; E Estey; Michael J Keating; Moshe Talpaz
Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia.
Leukemia 1997;11(10):1610-6.
1997: A W Bseiso; Hagop M Kantarjian; Jie Qiang Guo; Jorge Cortes; Moshe Talpaz; Charles Koller; Maher Albitar; Michael Keating; Ralph B Arlinghaus
Analysis of the BCR-ABL protein in Philadelphia chromosome-positive adult acute lymphocytic leukemia.
Leukemia 1997;11(9):1583-7.
1997: EJ Rodriguez-Monge; Jorge E Cortes; Susan O'Brien; Moshe Talpaz; Hagop M Kantarjian
Thiotepa for the treatment of thrombocythemia in patients with Philadelphia chromosome positive chronic myelogenous leukemia.
Cancer 1997;80(3):396-400.
1997: Moshe Talpaz; Hagop M Kantarjian; Susan O'Brien; Razelle Kurzrock
The M.D. Anderson Cancer Center experience with interferon-alpha therapy in chronic myelogenous leukaemia.
Baillière's clinical haematology 1997;10(2):291-305.
1997: J Cortes; Hagop M Kantarjian; Sergio Giralt; Moshe Talpaz
Natural history and staging of chronic myelogenous leukaemia.
Baillière's clinical haematology 1997;10(2):277-90.
1997: Hagop M Kantarjian; Susan M O'Brien; Elihu Estey; Sergio Giralt; Miloslav Beran; Mary Beth Rios; Michael Keating; D de Vos; Moshe Talpaz
Decitabine studies in chronic and acute myelogenous leukemia.
Leukemia 1997;11 Suppl 1():S35-6.
1996: Steven M Kornblau; Varsha Gandhi; H M Andreeff; Miloslav Beran; Hagop M Kantarjian; Charles Koller; Susan O'Brien; William Plunkett; Elihu Estey
Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
Leukemia 1996;10(10):1563-9.
1996: H M Ghaddar; Sherry Pierce; Hagop M Kantarjian; Emil J Freireich; Michael J Keating; Elihu H Estey
Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia.
Leukemia & lymphoma 1996;22(1-2):71-6.
1996: Paolo Anderlini; H M Ghaddar; Terry L Smith; Sherry Pierce; Hagop M Kantarjian; Susan O'Brien; Michael J Keating; Emil J Freireich; Elihu H Estey
Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first.
Leukemia 1996;10(6):964-9.
1996: I F Khouri; Hagop M Kantarjian; Moshe Talpaz; Sergio Giralt; M O Rios; Jeane Hester; Richard E Champlin; Albert Deisseroth
Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: the MD Anderson experience.
Bone marrow transplantation 1996;17(5):775-9.
1996: Hagop M Kantarjian; Susan O'Brien; Paolo Anderlini; Moshe Talpaz
Treatment of myelogenous leukemia: current status and investigational options.
Blood 1996;87(8):3069-81.
1996: Hagop M Kantarjian; Elihu H Estey; M A Keating
New chemotherapeutic agents in acute myeloid leukemia.
Leukemia 1996;10 Suppl 1():S4-6.
1996: Paolo Anderlini; Mario Luna; Hagop M Kantarjian; Susan O'Brien; Sherry Pierce; Michael J Keating; Elihu H Estey
Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes.
Leukemia 1996;10(4):600-8.
1996: S M Escudier; M Albitar; LE Robertson; Michael Andreeff; Sherry Pierce; Hagop M Kantarjian
Acute lymphoblastic leukemia following preleukemic syndromes in adults.
Leukemia 1996;10(3):473-7.
1996: Hagop M Kantarjian; Miloslav Beran; Susan O'Brien; L Robertson; Z Siddik; M Yoshida; L Y Yang; Mary Beth Rios; Michael J Keating; M Meyer
Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia.
Leukemia 1996;10(3):396-401.
1996: Koen van Besien; RC Mehra; Sergio Giralt; Hagop M Kantarjian; WC Pugh; I F Khouri; Y Moon; P Williams; Borje S Andersson; Donna Przepiorka; Philip L McCarthy; James L Gajewski; Albert Deisseroth; Fernando Cabanillas; Richard Champlin
Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology.
The American journal of medicine 1996;100(3):299-307.
1996: Zeev Estrov; Moshe Talpaz; Theodore F Zipf; Hagop M Kantarjian; S Ku; M V Ouspenskaia; Cheryl Hirsch-Ginsberg; Y Huh; G Yee; Razelle Kurzrock
Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181).
Journal of cellular physiology 1996;166(3):618-30.
1996: S M Escudier; Hagop M Kantarjian; Elihu H Estey
Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid.
Leukemia & lymphoma 1996;20(5-6):435-9.
1996: N Pollicardo; Susan O'Brien; E H Estey; M al-Bitar; Sherry Pierce; Michael Keating; Hagop M Kantarjian
Secondary acute promyelocytic leukemia. Characteristics and prognosis of 14 patients from a single institution.
Leukemia 1996;10(1):27-31.
1996: Terry L Smith; J Jack Lee; Hagop M Kantarjian; Sewa S Legha; Martin N Raber
Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):287-95.
1996: Alejandro Majlis; Terry L Smith; Moshe Talpaz; Susan O'Brien; Mary Beth Rios; Hagop M Kantarjian
Significance of cytogenetic clonal evolution in chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):196-203.
1995: J E Cortes; Hagop M Kantarjian
Acute lymphoblastic leukemia. A comprehensive review with emphasis on biology and therapy.
Cancer 1995;76(12):2393-417.
1995: H Alejandro Preti; Y O Huh; Susan M O'Brien; Michael Andreeff; S T Pierce; Michael Keating; Hagop M Kantarjian
Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosis.
Cancer 1995;76(9):1564-70.
1995: Paolo Anderlini; Robert S Benjamin; Franklin C Wong; Hagop M Kantarjian; Michael Andreeff; Steven M Kornblau; Susan O'Brien; B Mackay; Michael S Ewer; S A Pierce
Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(11):2827-34.
1995: C F Verschraegen; Hagop M Kantarjian; Cheryl Hirsch-Ginsberg; Ming-Sheng Lee; Susan O'Brien; Mary Beth Rios; Sanford A Stass; Michael Keating; Moshe Talpaz
The breakpoint cluster region site in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Clinical, laboratory, and prognostic correlations.
Cancer 1995;76(6):992-7.
1995: A E Chucrallah; Sanford A Stass; Y O Huh; Maher Albitar; Hagop M Kantarjian
Adult acute lymphoblastic leukemia at relapse. Cytogenetic, immunophenotypic, and molecular changes.
Cancer 1995;76(6):985-91.
1995: D Seong; Hagop M Kantarjian; J Y Ro; Moshe Talpaz; Jingping Xu; J R Robinson; Albert Deisseroth; Richard E Champlin; Michael J Siciliano
Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment.
Blood 1995;86(6):2343-9.
1995: J Cortes; Susan M O'Brien; Sherry Pierce; Michael J Keating; Emil J Freireich; Hagop M Kantarjian
The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia.
Blood 1995;86(6):2091-7.
1995: Mohammad A Haidar; X B Cao; Taghi Manshouri; L L Chan; Armand B. Glassman; Hagop M Kantarjian; Michael J Keating; Miloslav Beran; Maher Albitar
p16INK4A and p15INK4B gene deletions in primary leukemias.
Blood 1995;86(1):311-5.
1995: C F Verschraegen; Moshe Talpaz; Cheryl Hirsch-Ginsberg; R Pherwani; Mary Beth Rios; Sanford A Stass; Hagop M Kantarjian
Quantification of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia.
Blood 1995;85(10):2705-10.
1995: Elihu H Estey; Hagop M Kantarjian; Susan O'Brien; Steven M Kornblau; Michael Andreeff; Miloslav Beran; Sherry Pierce; Michael Keating
High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
Cytokines and molecular therapy 1995;1(1):21-8.
1995: Hagop M Kantarjian; Moshe Talpaz; Jeane Hester; E Feldman; Martin Korbling; J Liang; Mary Beth Rios; Terry L Smith; L Calvert; Albert Deisseroth
Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(3):553-9.
1995: Hagop M Kantarjian; Terry L Smith; Susan O'Brien; Miloslav Beran; Sherry Pierce; Moshe Talpaz
Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service.
Annals of internal medicine 1995;122(4):254-61.
1995: J E Cortes; Moshe Talpaz; Miloslav Beran; Susan M O'Brien; Mary Beth Rios; Sanford A Stass; Hagop M Kantarjian
Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results.
Cancer 1995;75(2):464-70.
1995: Jeane Hester; M Cecilia Dignani; Elias J Anaissie; Hagop M Kantarjian; Susan O'Brien; Emil J Freireich
Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection.
Journal of clinical apheresis 1995;10(4):188-93.
1994: Hagop M Kantarjian; Moshe Talpaz
Chemotherapy and bone marrow transplantation in the treatment of chronic myelogenous leukemia.
Seminars in oncology 1994;21(6 Suppl 14):8-13.
1994: Varsha Gandhi; Min Du; Hagop M Kantarjian; William Plunkett
Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia.
Leukemia 1994;8(9):1463-8.
1994: Hagop M Kantarjian; Susan O'Brien; T Smith; Elihu H Estey; Miloslav Beran; Alejandro Preti; Sherry Pierce; Michael J Keating
Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-adriamycin-dexamethasone (VAD) regimen.
British journal of haematology 1994;88(1):94-100.
1994: Hagop M Kantarjian
Adult acute lymphocytic leukemia: critical review of current knowledge.
The American journal of medicine 1994;97(2):176-84.
1994: H M Ghaddar; William Plunkett; Hagop M Kantarjian; Sherry Pierce; Emil J Freireich; Michael J Keating; Elihu H Estey
Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside.
Leukemia 1994;8(8):1269-74.
1994: H Alejandro Preti; Susan O'Brien; Sergio Giralt; Miloslav Beran; Sherry Pierce; Hagop M Kantarjian
Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients.
The American journal of medicine 1994;97(1):60-5.
1994: Hagop M Kantarjian; Moshe Talpaz; Borje Andersson; I Khouri; Sergio Giralt; Mary Beth Rios; Richard Champlin; Jeane Hester; Albert Deisseroth
High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia.
Bone marrow transplantation 1994;14(1):57-61.
1994: Alejandro Preti; Hagop M Kantarjian
Management of adult acute lymphocytic leukemia: present issues and key challenges.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(6):1312-22.
1994: J F Seymour; S A Pierce; Hagop M Kantarjian; Michael J Keating; Elihu H Estey
Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56).
Leukemia 1994;8(5):823-6.
1994: Y O Huh; WC Pugh; Hagop M Kantarjian; Sanford A Stass; A Cork; J M Trujillo; Michael J Keating
Detection of subgroups of chronic B-cell leukemias by FMC7 monoclonal antibody.
American journal of clinical pathology 1994;101(3):283-9.
1994: H Alejandro Preti; Hagop M Kantarjian
Acute lymphocytic leukemia in adults: an update.
Texas medicine 1994;90(1):52-9.
1994: Alejandro Preti; Hagop M Kantarjian; Elihu Estey; Y Huh; Michael Keating; Sherry Pierce; Cheryl Hirsch-Ginsberg; G Yee; Sanford A Stass
Characteristics and outcome of patients with acute lymphocytic leukemia and myeloperoxidase-positive blasts by electron microscopy.
Hematologic pathology 1994;8(4):155-67.
1993: Elias J Anaissie; Dimitrios P Kontoyiannis; SE Vartivarian; Hagop M Kantarjian; Susan O'Brien; Sergio Giralt; Borje S Andersson; C Karl; Richard E Champlin; Gerald P Bodey
Effectiveness of an oral triazole for opportunistic mold infections in patients with cancer: experience with SCH 39304.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1993;17(6):1022-31.
1993: Hagop M Kantarjian; Elihu Estey; Susan O'Brien; E Anaissie; Miloslav Beran; Sherry Pierce; L Robertson; Michael J Keating
Granulocyte colony-stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remission.
Cancer 1993;72(10):2950-5.
1993: Hagop M Kantarjian; Albert Deisseroth; Razelle Kurzrock; Zeev Estrov; Moshe Talpaz
Chronic myelogenous leukemia: a concise update.
Blood 1993;82(3):691-703.
1993: Zeev Estrov; Moshe Talpaz; Hagop M Kantarjian; Theodore F Zipf; K L McClain; Razelle Kurzrock
Heterogeneity in lineage derivation of Philadelphia-positive acute lymphoblastic leukemia expressing p190BCR-ABL or p210BCR-ABL: determination by analysis of individual colonies with the polymerase chain reaction.
Cancer research 1993;53(14):3289-93.
1993: I A Jaiyesimi; Hagop M Kantarjian; Elihu H Estey
Advances in therapy for hairy cell leukemia. A review.
Cancer 1993;72(1):5-16.
1993: Sergio Giralt; Hagop M Kantarjian; Moshe Talpaz; Mary Beth Rios; Auro Del Giglio; Borje S Andersson; Donna Przepiorka; Albert Deisseroth; Richard E Champlin
Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(6):1055-61.
1993: LE Robertson; R Hall; Michael J Keating; Elihu Estey; Hagop M Kantarjian; Peter McLaughlin; F B Hagemeister; William Plunkett
High-dose cytosine arabinoside in chronic lymphocytic leukemia: a clinical and pharmacologic analysis.
Leukemia & lymphoma 1993;10(1-2):43-8.
1993: Hagop M Kantarjian; Miloslav Beran; A Ellis; Leonard A Zwelling; Susan O'Brien; L Cazenave; Charles Koller; Mary Beth Rios; William Plunkett; Michael J Keating
Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.
Blood 1993;81(5):1146-51.
1993: Zeev Estrov; A B Markowitz; Razelle Kurzrock; Meir Wetzler; Hagop M Kantarjian; A Ferrajoli; Jordan U Gutterman; Moshe Talpaz
Suppression of chronic myelogenous leukemia colony growth by interleukin-4.
Leukemia 1993;7(2):214-20.
1993: Lian Zhao; Hagop M Kantarjian; J Van Oort; A Cork; J M Trujillo; Jan C Liang
Detection of residual proliferating leukemic cells by fluorescence in situ hybridization in CML patients in complete remission after interferon treatment.
Leukemia 1993;7(2):168-71.
1993: Hagop M Kantarjian; E H Estey; Michael J Keating
Treatment of therapy-related leukemia and myelodysplastic syndrome.
Hematology/oncology clinics of North America 1993;7(1):81-107.
1993: P M Derderian; Hagop M Kantarjian; Moshe Talpaz; Susan O'Brien; A Cork; Elihu Estey; Sherry Pierce; Michael Keating
Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis.
The American journal of medicine 1993;94(1):69-74.
1993: Hagop M Kantarjian; Moshe Talpaz
Long-term follow-up results of alpha interferon therapy in chronic myelogenous leukemia at M. D. Anderson Cancer Center.
Leukemia & lymphoma 1993;11 Suppl 1():169-74.
1992: Emil J Freireich; A Cork; Sanford A Stass; K B McCredie; Michael J Keating; Elihu H Estey; Hagop M Kantarjian; J M Trujillo
Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia.
Leukemia 1992;6(6):500-6.
1992: Hagop M Kantarjian; Michael J Keating; Elihu H Estey; Susan O'Brien; Sherry Pierce; Miloslav Beran; Charles Koller; E Feldman; Moshe Talpaz
Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(5):772-8.
1992: Hagop M Kantarjian; Moshe Talpaz; D Kontoyiannis; J Gutterman; Michael J Keating; E H Estey; Susan O'Brien; Mary Beth Rios; Miloslav Beran; Albert Deisseroth
Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(3):398-405.
1992: Hagop M Kantarjian; Elihu H Estey; Susan O'Brien; E Anaissie; Miloslav Beran; Mary Beth Rios; Michael J Keating; Jordan U Gutterman
Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia.
Blood 1992;79(4):876-81.
1992: Elihu H Estey; Razelle Kurzrock; Hagop M Kantarjian; Susan M O'Brien; K B McCredie; Miloslav Beran; Charles Koller; Michael J Keating; Cheryl Hirsch-Ginsberg; Y O Huh
Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA).
Blood 1992;79(4):882-7.
1991: Hagop M Kantarjian; Moshe Talpaz; Kapil Dhingra; Elihu Estey; Michael J Keating; S Ku; J Trujillo; Y Huh; Sanford A Stass; Razelle Kurzrock
Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia.
Blood 1991;78(9):2411-8.
1991: Hagop M Kantarjian; Moshe Talpaz; Michael J Keating; Elihu H Estey; Susan O'Brien; Miloslav Beran; K B McCredie; Jordan U Gutterman; Emil J Freireich
Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cancer 1991;68(6):1201-7.
1991: Hagop M Kantarjian; Moshe Talpaz; Charles F LeMaistre; J Spinolo; G Spitzer; JC Yau; K Dicke; Sundar Jagannath; Albert Deisseroth
Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia.
Cancer 1991;67(12):2959-65.
1991: Elihu H Estey; Razelle Kurzrock; Moshe Talpaz; K B McCredie; Susan O'Brien; Hagop M Kantarjian; Michael J Keating; Albert Deisseroth; Jordan U Gutterman
Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes.
British journal of haematology 1991;77(3):291-5.
1991: Hagop M Kantarjian; J Schachner; Michael J Keating
Fludarabine therapy in hairy cell leukemia.
Cancer 1991;67(5):1291-3.
1991: Hagop M Kantarjian; C Childs; Susan O'Brien; Y Huh; Miloslav Beran; J Schachner; Charles Koller; Michael J Keating
Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia.
The American journal of medicine 1991;90(2):223-8.
1990: L M Haber; C C Childs; Cheryl Hirsch-Ginsberg; K Nellis; Hagop M Kantarjian; A Cork; J M Trujillo; Sanford A Stass
Strategy for breakpoint cluster region analysis in chronic myelocytic leukemia in a routine clinical laboratory.
American journal of clinical pathology 1990;94(6):762-7.
1990: R Walters; Hagop M Kantarjian; Michael J Keating; E H Estey; J Trujillo; A Cork; K B McCredie; Emil J Freireich
The importance of cytogenetic studies in adult acute lymphocytic leukemia.
The American journal of medicine 1990;89(5):579-87.
1990: Hagop M Kantarjian; J R Redman; Michael J Keating
Fludarabine phosphate therapy in other lymphoid malignancies.
Seminars in oncology 1990;17(5 Suppl 8):66-70.
1990: Hagop M Kantarjian; Cheryl Hirsch-Ginsberg; G Yee; Y Huh; Emil J Freireich; Sanford A Stass
Mixed-lineage leukemia revisited: acute lymphocytic leukemia with myeloperoxidase-positive blasts by electron microscopy.
Blood 1990;76(4):808-13.
1990: K A Dicke; M J Dicke-Evinger; J A Spinolo; E H Estey; Hagop M Kantarjian; G Spitzer
Double intensification including autologous bone marrow transplantation (ABMT) in AML: long term follow-up and detection of residual disease.
Bone marrow transplantation 1990;6 Suppl 1():27-34.
1990: Hagop M Kantarjian; Ronald S Walters; Michael J Keating; Terry L Smith; Susan O'Brien; Elihu H Estey; Y O Huh; J Spinolo; K Dicke; Bart Barlogie
Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(6):994-1004.
1990: Hagop M Kantarjian; Raymond Alexanian; Charles Koller; Razelle Kurzrock; Michael J Keating
Fludarabine therapy in macroglobulinemic lymphoma.
Blood 1990;75(10):1928-31.
1990: Elihu H Estey; D Dixon; Hagop M Kantarjian; Michael J Keating; K McCredie; Gerald P Bodey; Razelle Kurzrock; Moshe Talpaz; Emil J Freireich; Albert Deisseroth
Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor.
Blood 1990;75(9):1766-9.
1990: Hagop M Kantarjian; Razelle Kurzrock; Moshe Talpaz
Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia.
Hematology/oncology clinics of North America 1990;4(2):389-404.
1990: Razelle Kurzrock; Hagop M Kantarjian; M Shtalrid; Jordan U Gutterman; Moshe Talpaz
Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course.
Blood 1990;75(2):445-52.
1990: Hagop M Kantarjian; Michael J Keating; Terry L Smith; Moshe Talpaz; K B McCredie
Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia.
The American journal of medicine 1990;88(1):1-8.
1990: Hagop M Kantarjian; R L Walters; Michael J Keating; Elihu H Estey; Susan O'Brien; J Schachner; K B McCredie; Emil J Freireich
Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia.
Cancer 1990;65(1):5-8.
1990: Elihu H Estey; Hagop M Kantarjian; Miloslav Beran; K B McCredie; Michael J Keating; Albert Deisseroth; Jordan U Gutterman
Treatment of poor-prognosis, newly diagnosed acute myelogenous leukemia with high-dose cytosine arabinoside (Ara-C) and rHUGM-CSF.
Haematology and blood transfusion 1990;33():732-6.
1989: Susan O'Brien; Hagop M Kantarjian; Michael Keating; G Gagnon; A Cork; J Trujillo; K B McCredie
Association of granulocytosis with poor prognosis in patients with acute myelogenous leukemia and translocation of chromosomes 8 and 21.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(8):1081-6.
1989: Hagop M Kantarjian; Ronald S Walters; Michael J Keating; Bart Barlogie; K B McCredie; Emil J Freireich
Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemia.
Cancer 1989;64(1):16-22.
1989: Ming-Sheng Lee; A LeMaistre; Hagop M Kantarjian; Moshe Talpaz; Emil J Freireich; J M Trujillo; Sanford A Stass
Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction.
Blood 1989;73(8):2165-70.
1989: K M Taylor; M Shetta; Moshe Talpaz; Hagop M Kantarjian; S Hardikar; A Craig Chinault; K B McCredie; G Spitzer
Myeloproliferative disorders: usefulness of X-linked probes in diagnosis.
Leukemia 1989;3(6):419-22.
1989: Hagop M Kantarjian; Michael J Keating; Ronald S Walters; Charles Koller; K B McCredie; Emil J Freireich
Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia.
Cancer 1989;63(5):813-7.
1989: A LeMaistre; Ming-Sheng Lee; Moshe Talpaz; Hagop M Kantarjian; Emil J Freireich; Albert Deisseroth; J M Trujillo; Sanford A Stass
Ras oncogene mutations are rare late stage events in chronic myelogenous leukemia.
Blood 1989;73(4):889-91.
1989: L J Horwitz; Hagop M Kantarjian; Sundar Jagannath; Michael J Keating; K B McCredie; G Spitzer; L Vellekoop; A R Zander; K A Dicke
Piperazinedione plus total body irradiation: an alternative preparative regimen for allogeneic bone marrow transplantation in advanced phases of chronic myelogenous leukemia.
Bone marrow transplantation 1989;4(1):101-5.
1988: Hagop M Kantarjian; M Shtalrid; Razelle Kurzrock; M Blick; W T Dalton; A LeMaistre; Sanford A Stass; K B McCredie; Jordan U Gutterman; Emil J Freireich
Significance and correlations of molecular analysis results in patients with Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia.
The American journal of medicine 1988;85(5):639-44.
1988: Hagop M Kantarjian; Ronald S Walters; T L Smith; Michael J Keating; Bart Barlogie; K B McCredie; Emil J Freireich
Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia.
Blood 1988;72(5):1784-9.
1988: Ming-Sheng Lee; Kun-Sang Chang; Emil J Freireich; Hagop M Kantarjian; Moshe Talpaz; J M Trujillo; Sanford A Stass
Detection of minimal residual bcr/abl transcripts by a modified polymerase chain reaction.
Blood 1988;72(3):893-7.
1988: Hagop M Kantarjian; D Dixon; Michael J Keating; Moshe Talpaz; Ronald S Walters; K B McCredie; Emil J Freireich
Characteristics of accelerated disease in chronic myelogenous leukemia.
Cancer 1988;61(7):1441-6.
1988: Hagop M Kantarjian; Michael J Keating; Ronald S Walters; K B McCredie; Emil J Freireich
The characteristics and outcome of patients with late relapse acute myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(2):232-8.
1988: Hagop M Kantarjian; Moshe Talpaz; Jordan U Gutterman
Chronic myelogenous leukemia--past, present, and future.
Hematologic pathology 1988;2(2):91-120.
1987: Hagop M Kantarjian; Michael J Keating
Therapy-related leukemia and myelodysplastic syndrome.
Seminars in oncology 1987;14(4):435-43.
1987: Ronald S Walters; Hagop M Kantarjian; M J Keating; Moshe Talpaz; C C Childs; K B McCredie; Emil J Freireich
Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and adriamycin infusions plus high-dose decadron.
Cancer 1987;60(8):1708-12.
1987: Hagop M Kantarjian; Michael J Keating; K B McCredie; R Walters; Moshe Talpaz; Terry L Smith; Emil J Freireich
Old age: a sign of poor prognosis in patients with chronic myelogenous leukemia.
Southern medical journal 1987;80(10):1228-32.
1987: Hagop M Kantarjian; Michael J Keating; Moshe Talpaz; Ronald S Walters; Terry L Smith; A Cork; K B McCredie; Emil J Freireich
Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients.
The American journal of medicine 1987;83(3):445-54.
1987: Hagop M Kantarjian; Moshe Talpaz; Jordan U Gutterman
Biologic therapy of chronic myelogenous leukemia.
Oncology (Williston Park, N.Y.) 1987;1(7):35-40, 48-9, 52.
1987: Moshe Talpaz; Hagop M Kantarjian; K B McCredie; M J Keating; J Trujillo; Jordan U Gutterman
Clinical investigation of human alpha interferon in chronic myelogenous leukemia.
Blood 1987;69(5):1280-8.
1987: Susan O'Brien; Hagop M Kantarjian; Moshe Talpaz; A Cork; J Trujillo; Miloslav Beran
The effect of long-term marrow culture on the nonadherent Philadelphia chromosome-positive clone in chronic myelogenous leukemia: preliminary observations.
Hematologic pathology 1987;1(3):167-72.
1987: Michael J Keating; Elihu Estey; Hagop M Kantarjian; R Walters; T Smith; K B McCredie; Emil J Freireich
Comparison of results of salvage therapy in adult acute myelogenous leukemia.
Acta haematologica 1987;78 Suppl 1():120-6.
1987: Hagop M Kantarjian; Moshe Talpaz; Razelle Kurzrock; M J Keating; K B McCredie; Jordan U Gutterman; Emil J Freireich
Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia.
Acta haematologica 1987;78 Suppl 1():70-4.
1986: Hagop M Kantarjian; Michael J Keating; Ronald S Walters; E H Estey; K B McCredie; T L Smith; W T Dalton; A Cork; J M Trujillo; Emil J Freireich
Acute promyelocytic leukemia. M.D. Anderson Hospital experience.
The American journal of medicine 1986;80(5):789-97.